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ABSTRACT  
 
INVESTIGATING AND MANIPULATING IMMUNE 
RESPONSES TO HEPATOTROPIC PATHOGENS USING 
SYNTHETIC DNA 
 
Nyamekye Obeng-Adjei 
 
David B. Weiner 
 
 Hepatotropic pathogens, such as Hepatitis B virus (HBV), Hepatitis C virus (HCV) and 
malaria Plasmodium often escape cellular immune clearance, resulting in chronic 
infections. With billions at the risk of infection, the need for an immune therapy that will 
incite protective immune responses against these pathogens is more important now than 
ever. To develop effective therapies against these pathogens, it is important to understand 
the mechanisms by which liver-primed CD8 T cells become defective. In this report, I 
directly compared liver-primed CD8 T cells to secondary lymphoid tissue-primed CD8 T 
cells for differentiation, function, and memory programming in a highly controlled 
fashion. We used hydrodynamic tail vain injection of synthetic plasmids to establish 
liver-specific antigen expression in the P14 transgenic mouse model, and studied the 
priming of CD8 T cells. Intrahepatically activated CD8 T cells exhibited unique 
expansion, memory differentiation, polyfunctionality and cytotoxicity compared to T 
cells primed in the periphery. The difference in their expansion resulted in lower memory 
CTL frequency, which led to reduced protection against lethal viral challenge. These 
results demonstrated that defective liver priming of naïve CD8 T cells contributes to the 
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lower frequency of antigen-specific CTLs observed during liver infection in HBV and 
HCV patients, which helps these pathogens to escape immune clearance.  
The results from the study provide evidence that, the eradication of HBV and HCV 
infected hepatocytes will require both the induction of a strong antigen-specific immune 
response and the subsequent deployment of that response towards the liver. We therefore 
assessed the ability of a synthetic DNA vaccine encoding a recombinant plasmid of the 
HBcAg and HBsAg to drive immunity in the liver. Intramuscular vaccination 
accompanied by electroporation induced both strong antigen-specific T cell and high titer 
antibody responses systematically and in the liver. Furthermore, immunized mice showed 
strong cytotoxic responses that eliminate adoptively transferred HBV-coated target cells 
in the spleen and liver. These data provide important insight into the generation of 
peripheral immune responses that are recruited to the liver; an approach that could be 
beneficial in the search for vaccines or immune-therapies for liver disease.  
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Chapter 1 – Introduction 
 
“A large red organ thoughtfully provided by nature to be bilious with. The sentiments 
and emotions, which every literary anatomist now knows to haunt the heart, were 
anciently believed to infest the liver; and even Gascoygne, speaking of the emotional side 
of human nature, calls it "our hepaticall parte." It was at one time considered the seat of 
life; hence its name— liver, the thing we live with.” - Ambrose Bierce, editor, journalist, 
fabulist and satirist.   
 
 
1.1 The liver 
 
The liver is the second largest organ behind the skin in many animals. It is however the 
largest internal organ in the human body and weighs a little over 1, 500 grams. The organ 
is located between the diaphragm and the abdominal cavity. It sits on top of the right 
kidney, stomach and the intestines. The liver is an essential organ that is absolutely vital 
for survival. It performs various but connected functions including synthesizing nutrients 
needed for living and growing, and detoxifying the blood of harmful substances. In 
addition to these functions, the liver regulates the immune response to prevent hepatic 
damage induced by immune cells.   
The liver is divided into two major lobes – the right and the left lobes. The separation of 
these lobes is based on two branches (right and left) of the hepatic artery and the portal 
vein. Both the hepatic artery and the portal vein run directly through the liver and provide 
the liver with 1500 mL of blood per minute. The hepatic portal vein brings in about 70% 
of this blood and the hepatic arteries account for the rest of the blood flow. The portal 
vein carries venous blood (deoxygenated blood) that contains digested nutrients from the 
 2 
gastrointestinal tract and pancreas, to the liver for metabolism. Carbohydrates, peptides, 
lipids and other nutrients are all carried to the liver through the portal vein.  
 
1.2 Liver infections 
 
The liver is functionally connected to all 72 organs in the human body through 500 vital 
functions that have been identified. Examples of these functions are: the production of 
proteins that forms part of the blood plasma, the conversion of extra glucose into 
glycogen for storage, the production of special compounds and proteins that regulate lipid 
transport throughout the body, breaking down harmful substances into simple soluble 
substances that can be cleared out of the body, the regulation of blood peptides, lipids and 
carbohydrates, the processing of hemoglobin to utilize the iron, and last but not the least, 
the removal of pathogens and other foreign substances from the bloodstream to prevent 
infection.  
The many functions that are performed through the regulation of the blood contents and 
the continuous stream of both oxygenated and deoxygenated blood through the liver 
make the organ readily accessible to most pathogens. Bacteria and other food pathogens 
from the gut have direct access to the liver through the portal vein. Other blood-borne 
pathogens reach the liver before they gain access to most tissues. Apart from fully 
assembled pathogens, the liver is also exposed to several antigens that can cause damage 
to the organ if the body induces immune responses towards such antigens. The liver 
microenvironment has a clever way of dealing with pathogens without inciting the body’s 
defense system, which can do more harm than good. The liver has been shown to clear 
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many blood-borne pathogens using scavenger cells that surround the hepatocytes. These 
scavenger cells uptake pathogens and destroy them just like phagocytes will engulf 
foreign particles to kill and digest them. The two most important cells that are involved in 
protecting hepatocytes from infection are liver sinusoidal endothelial cells (LSECs) and 
Kupffer cells.  
 
1.2.1 Liver sinusoidal endothelial cell (LSEC) 
 
Liver or hepatic sinusoidal endothelia cells make up 50% of the non-parenchymal hepatic 
cells, which can be found in the “non-functional” parts of the liver. These cells separate 
the hepatic cells from passing blood, which is an important aspect in preventing 
pathogenic infections in the liver (Braet et al., 2004). LSECs express many scavenger 
receptors, which regulate the trade of proteins and other important materials between the 
liver parenchyma and blood, while protecting the parenchyma from infectious substances 
that pass through the blood. It is believed that LSECs preferentially eliminate denatured 
or manipulated proteins, extracullar matrices and some lipoproteins (Enomoto et al., 
2004). The most important feature the LSEC possess are the “bristle-coated 
micropinocytotic vesicles” and “macropinocytotic vesicles” in their cytoplasm and 
lysosomal enzymes required for the degradation of foreign substances that the cell 
engulfs (Wise E., 1970, 1972). Although LSECs are assembled with small spaces (about 
100nm in diameter) between the cells, 20nm particles are unlikely to pass through 
because of the presence of extracellular matrix that has been positioned between these 
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cells (Schlepper-Schafer, 1986). This is helpful in shielding the hepatocytes from foreign 
objects.  
1.2.2 Kupffer cells 
 
Kupffer cells, also referred to as stellate macrophages are currently the only identified 
liver resident macrophage population (Haubrich, 2004). They can be found around the 
walls of liver endothelial cells as part of the mononuclear phagocyte system. These cells, 
like many macrophages, originate from the bone marrow as monoblasts and then 
differentiate into monocytes. They then migrate into the blood as peripheral blood 
monocytes and subsequently mature into Kupffer (macrophage) cells (Naito et al., 1997). 
Kupffer cells have previously been confused as endothelial cells due to the difficulties 
involved in isolating them. These cells specialize in destroying foreign microbes, proteins 
and cancer cells that may infiltrate the liver. Like other macrophages, they destroy 
microbes by engulfment. Once a Kupffer cell engulfs a pathogen, it traps the pathogen in 
the phagosome, which is then linked with a lysosome to form a phagolysosome. 
Degradation enzymes from the phagolysosome then digest the pathogen. In order to 
prevent destruction by Kupffer cells, some pathogens such as Plasmodium spp. 
sporozoites infect and destroy Kupffer cells before infecting the hepatocytes.  
 
1.3 Major liver pathogens 
 
Despite the great deal of effort liver scavenger cells put forth to prevent hepatic cell 
infections, there are several pathogens that are able to use the liver as a site of infection, 
replication, amplification and sometimes, to escape immune response. Viruses like 
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Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D and Hepatitis E preferentially infect 
liver cells, while pathogens like malaria Plasmodium infect the liver among other tissues.  
When these pathogens are left untreated, they lead to liver damages and in extreme cases 
death. Liver infection by these pathogens will be described in detail in the following 
sections. 
 
1.3.1 Hepatitis A virus 
 
Hepatitis A (HAV) is a picornavirus; a non-enveloped, positive-stranded RNA virus with 
an icosahedral capsid. This virus is a food-borne pathogen that usually spreads when a 
person ingests a solid food or liquid contaminated with feces from infected individuals. 
The virus passes through mucosal epithelial cells after infection to enter the blood. It 
travels through the blood where it infects Kupffer cells before crossing the space of Dissé 
to infect hepatocytes. HAV replicates in the liver and has been shown to lack the ability 
to replicate outside the liver, in vivo.  
There is only one known HAV serotype but as many as seven genotypes (I 
through VII). Almost all humans HAV strains are genotype I and III, with 80% of the 
infection being genotype I (Costa-Mattioli et al., 2003). Although HAV infection does 
not lead to chronic liver disease, infected individuals usually suffer from fever, loss of 
appetite, diarrhea, jaundice, malaise, fatigue and abdominal pain.  These symptoms can 
last for a few weeks or several months, depending on the infected individual. While there 
is no available treatment, an effective vaccine program has been in place since the early 
1990s. Although these vaccine programs have drastically reduced the infection rate in 
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developed countries, there are still about 1.4 million cases of HAV every year around the 
world. These infections are usually in countries with poor sanitation and water treatment 
records (Pintò et al., 2012).  
There is an increase in the liver enzyme alanine transferase (ALT) in the blood during the 
acute infection stage, but there are no data available that show HAV-mediated 
cytotoxicity. It is believed that liver pathology seen after infection is immune-mediated.  
 
1.3.2 Hepatitis B virus 
 
Human Hepatitis B virus (HBV) is a double stranded DNA virus that is part of the 
Hepadnaviridae family. Like all Hepadnaviridae viruses, human HBV infects the liver. 
With a virion diameter of 42nm, HBV is considered to be one of the smallest human 
viruses. It is made up of an outer lipid envelope and a nucleocaspsid core protein. The 
lipid envelope contains proteins that are involved in viral attachment and entry. These 
proteins are known as hepatitis B surface antigen proteins (HBsAg) or Australia antigens 
in some old literatures. The presence of HBsAg proteins or antibodies to HBsAg in the 
blood is usually used to confirm an HBV infection or disease. The nucleocapsid, which is 
made of proteins called hepatitis B core antigen proteins (HBcAg), encloses the viral 
DNA polymerase and DNA. There are as many as 9 genotypes of human HBV (genotype 
A- I) found in different geographical locations, with 8% divergence between genotypes. 
There are over 24 serotypes that have been described with 8 genotypes (A-H) (Kramvis et 
al., 2005).  
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Although no particular receptor on hepatocytes has been identified to aid the entry of 
HBV, it is known that HBV attachment to hepatocytes requires interaction with a highly 
sulphated proteoglycan. After attachment and entry, the viral DNA is transcribed into 
mRNA, which is then translated into the core proteins and DNA polymerase.  
The incubation period for the virus ranges from 30 to 180 days with an average period of 
90 days. While most infected individuals do not show any symptoms during acute 
infection, a small population suffers from fatigue, jaundice, nausea and abdominal pains. 
Chronic infection on the other hand, leads to liver damage, cirrhosis of the liver and 
eventually, liver cancer, if left untreated. Over 2 billion people have been infected with 
the virus, with over 370 million chronically infected. About half a million people die each 
year from liver complications that arise from HBV infection (Block et al., 2007; 
Rodríguez-Frias F, 2008).   
 Most acutely HBV-infected individuals clears the virus by themselves and do not need 
treatment but chronic infected patients are usually placed on antiviral therapies. Currently 
available antiviral therapies are capable of inhibiting viral replication but unable to clear 
infection completely. The best method of prevention is the use of vaccines. The current 
vaccine induces protective antibodies in 85-95% of immunized immuno-competent 
individuals.  
 
1.3.3 Hepatitis C virus 
 
Hepatitis C virus (HCV) like HBV is a small virus  (about 60nm) that infects the human 
liver. Unlike HBV, HCV is a positive-sense single-stranded RNA virus from the 
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Flaviviridae family of viruses. HCV, like most RNA viruses, contains both structural 
proteins and non-structural proteins. The structural proteins include one core protein and 
two envelope proteins (E1 and E2) while the non-structural proteins consist of 7 proteins 
(NS1, NS2, NS3, NS4A, NS4B, NS5A and NS5B). The divergence within HCV 
genotypes are much higher (about 30-35%) than that of HBV. This great genetic diversity 
contributes to the difficulties that arise in the development of an effective immunotherapy 
for HCV (Nakano et al., 2012).  
HCV uses the envelope proteins E1 and E2 to bind and initiate entry into hepatocytes. 
The virus attaches itself to HSPGs, and then binds to multiple receptors on the surface of 
hepatocytes. These receptors include low-density lipoprotein (LDL) receptor, scavenger 
receptor B1, claudin-1, occludin and CD81, which help the virus to endocytose after 
binding. HCV replication occurs on intracellular lipid membranes and virion release take 
place through very low-density lipoprotein secretory pathways.  
The incubation period for an HCV infection is anywhere from 2 weeks to 6 months. Only 
20% of acute infected individuals are symptomatic. These symptoms are similar to most 
liver injections; fatigue, nausea, jaundice and abdominal pains (Maheshwari et al.). Over 
75% of infected patients develop chronic infection and 60-70% of the chronically 
infected develop liver disease. HCV accounts for 25% of all liver cancers. There are 
about 170 million people chronically infected and more than 350 000 die every year from 
HCV-related liver complications.  
There is no vaccine for HCV infection. Therapies available reduce viral replication but do 
not result in viral clearance. Treatments, which involve antiviral and interferon therapies, 
respond differently to each viral genotype (Ozaras and Tahan, 2009).   
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1.3.4 Hepatitis D and E viruses 
 
Hepatitis D and E (HDV and HEV) are the two remaining viruses that infect the liver and 
cause hepatitis, although they are less prevalent than the other hepatitis viruses. Both 
HDV and HEV are RNA viruses, but unlike HDV, HEV is a non-enveloped particle.  
HDV is enclosed in an envelope made up of the three surface antigen proteins of HBV. 
HDV is a subviral satellite that requires the presences of HBV to infect the human liver. 
While, HDV does not induce liver disease, it is able to exacerbate complications that 
arise from HBV infections (Riaz et al., 2011).  
Currently, there are 8 known genotypes of HDV and 4 for HEV. Though multiple 
serotypes of these viruses have not been characterized, the different genotypes of HEV 
can be sub-classified into different subtypes.  
Over 15 million HEV infections occur each year around the world with half a million 
deaths from HEV complications. The virus passes through contaminated food and water 
supplies and makes it way to the liver, where it spends about 40 days incubating. 
Symptoms following HEV infections are very similar to that of HAV; jaundice, nausea 
and abdominal pains (Kumar et al., 2013).  
There are no specific treatments for either virus. HDV is usually prevented with HBV 
vaccines, since HDV infection is dependent on HBV infection. HEV vaccines are 
currently only available in China.   
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1.3.4 Plasmodium Malaria 
 
The Plasmodium, which is a genus of Apicomplexen parasites, uses the liver as a site for 
multiplication and to escape immune responses. The plasmodium, unlike liver viruses, 
does not infect and reside in the liver to manifest clinical symptoms to its disease, 
malaria. When a female anopheles mosquito bites the human skin, it can transmit a vector 
form of the parasite, the sporozoite, into the blood. From there, sporozoite migrates 
quickly into the liver to escape detection by the innate immune system. In the liver, it 
uses circumsporozoite protein (CSP) and thrombospondin-related anonymous protein 
(TRAP) to bind to Kupffer cells, where it proceeds to infect the hepatocytes. Binding to 
Kupffer cells allows the parasite to overcome the scavenger receptors of the sinusoidal 
endothelia barrier and therefore, escapes phargocytosis. After the parasite invades the 
hepatocyte, it transforms into an asexually reproducing merozoite. The parasite spends a 
week to a month asexually and asymptomatically replicating in the liver. Then thousands 
of merozoites rupture the liver cells and make their way to the sinusoids where they 
infect red blood cells.  They escape being recognized by the immune system by coating 
their surface with hepatocyte membrane until they reach the targeted erythrocyte. 
Symptoms of fever occur when merozoites replicate and bust out of erythrocytes. Other 
symptoms include vomiting and headaches (Nayyar et al., 2012).  
It is estimated that over 200 million cases of malaria occur each year, with over a million 
deaths. This disease is epidemic in poor countries, especially regions of sub-Saharan 
Africa. There are several medications available for the treatment of malaria and 
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prevention. Unfortunately, there are also several undesirable effects associated with these 
medications. Perhaps the most disastrous aspect of malaria treatment is the parasitie’s 
resistance to drugs, which has made prevention and treatment of malaria infection 
extremely difficult (Aguiar et al., 2012).  
There is currently no vaccine available for malaria. There are several vaccines in different 
stages of clinical trials across the globe but Word Health Organization has approved none 
for commercial use. The best way to prevent malaria infections is to control the breeding 
of the vector host, mosquito (Vaughan and Kappe, 2012).  
 
1.4 Immune defenses in the liver 
 
Although the liver has many mechanisms in place to control pathogenic infections, some 
pathogens are able to overcome these immune barriers to establish chronic infections. 
Before pathogens such as HBV, HCV and malaria Plasmodium can establish infection, 
they have to escape both innate and adaptive immune recognition by taking advantage of 
the specialized tolerogenic environment of the liver.  
 
1.4.1 The innate immune defense of the liver   
 
The innate immune system is the first line of defense that protects a host organism from 
infection by foreign pathogens. In humans, it prevents the free growth of bacteria and 
non-specifically attacks and destroys other pathogens that may invade the body. Since the 
innate immune system is non-specific, there is no need for cell priming or previous 
engagement.  There are several bone marrow-derived cells that are associated with the 
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innate immune system which also play a role in clearing pathogens in the liver. These are 
natural killer cells (NK), macrophages, neutrophils and dendritic cells. Kupffer cells, 
LSEC and liver stellate cells are specialized cells in the liver that operate as the first line 
of defense to prevent pathogenic infections.  
To detect pathogens, the innate immune cells use pattern recognition receptors (PRR) 
such as toll-like receptors (TLRs) and cytosolic helicases to distinguish pathogen 
antigens from host proteins. Although there are some differences between PRR 
expression on splenic and hepatic innate cells, both cell populations can recognize 
pathogens in similar fashion (Wu et al., 2009).  
Hepatotropic pathogens like most pathogens have developed mechanisms to overcome or 
invade the innate system. This is an important step for the hepatotropic pathogens to gain 
entry into the hepatic environment and to replicate after infection. The best example is 
Hepatitis C virus. To gain entry, HCV expresses a polyprotein precursor that induces a 
unique response that initiates autophagy in the host cells. This response promotes HCV 
RNA replication and subsequently suppresses type I interferon (IFN) responses.  The 
virus also inhibits recognition by TLRs through the cleaving of IFNB-promoter 
stimulator 1, an important mitochondrial-signaling molecule that is involved in the 
production of IFN cytokines (Chen, 2011).  HBV, on the other hand, escapes recognition 
sensing by synthesizing genomic materials in a capsid and suppressing TLRs on liver 
cells (Wieland et al., 2004).  
The Plasmodium parasite that causes malaria uses a unique mechanism to escape 
detection. After infecting the Kupffer cells, the sporozoites create a ‘parasitophorous 
vascoule’ in these cells to prevent their molecules from being directly detected by 
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membrane-bound PRR. Sporozoites also prevent the respiratory burst in Kupffer cells 
and cover their surface molecules with hepatocyte membranes after bursting out of 
hepatocytes (Usynin et al., 2007).  
It is obvious that the liver possess competent innate immune cells that are capable of 
clearing pathogens, food antigens and dead/cancer cells. However, some pathogens have 
developed illusive mechanisms to evade the immune responses induced by these cells.  
 
1.4.2 Liver adaptive immunity and tolerance 
 
The adaptive immune response is a highly specific and specialized system of eliminating 
pathogens, foreign substances, dead cells and cancer cells from an organism. The two 
major lymphocytes of this system are the T and B cells. When pathogens invade the 
body, innate immune cells do their best to clear them, but when the innate system fails, it 
initiates the adaptive immune system, which recognize specific, non-self antigens on the 
pathogens and eliminate them from the host. The most important aspect of the adaptive 
immune system is its ability to generate immunological memory. Immunological memory 
improves the specificity of the response and reduces the response period after pathogen 
re-invasion. The humoral response (B cells) clears pathogens by neutralizing the 
pathogen with antibodies produced by activated or memory B cells, while the cellular 
response (T cell) destroys cells infected by these pathogens.  
The liver holds an enormous population of immune cells, mostly activated T cells. CD8 T 
cells, which are commonly cytotoxic, are more likely to be found in the liver at any 
particular time than CD4 T cells. Despite the huge population of CD8 T cells found in the 
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liver, the environment mostly exhibits tolerogenic effects towards foreign antigens. Liver 
transplantation within the same mammalian species is less likely to result in rejection, 
even when immunosuppressive drugs are not involved. This is in sharp contrast to other 
tissues like kidney, spleen, pancreas and skin, where rejection is inevitable (Calne, 2002). 
Many independent studies have suggested that the liver confers tolerance to prevent 
immune response towards liver antigens, which are mostly food antigens. Although the 
exact mechanism has not been fully elucidated, the liver is found to increase immune 
suppressive factors and negative immune regulators and to delete immune cells. Liver 
tolerance has also been attributed to professional APC (innate) antigen presentation and 
priming of adaptive cells within the liver (Crispe and Mehal, 1996).  
Successful hepatotropic human pathogens such as HBV, HCV and Plasmodium, take 
advantage of this suboptimal liver immune response to establish chronic infection (Terilli 
and Cox, 2012).  
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1.5 Aims of this thesis 
 
In this thesis, we tested an important hypothesis that aims to understand the defect in host 
cellular immunity in the liver after pathogenic invasion and explore ways to enhance 
immune response in the liver using a synthetic DNA vaccine platform.   
Many liver immunologists consider the priming of naïve T cells in the liver renders those 
T cells ineffective. We believe the liver evolved this tolerogenic mechanism to prevent 
hepatic injuries and insults that can occur during host immune attack. This mechanism 
has become the liver’s own ‘Achilles heel’ in terms of preventing some chronic 
infections such as HBV and HCV. Performing head to head comparison of hepatic T cell 
priming and lymphoid T cell priming, we detected defective effector and memory T cell 
differentiation after liver priming.  
We hypothesized that induction of cellular and humoral immunity through the priming of 
immune cells in local lymph nodes using plasmid DNA vaccine would be effective in 
clearing pathogenic liver infections. We used different models to study how to direct 
immune response to the liver. We believe the generation of peripheral immune responses 
that can be recruited to the liver will be an important approach that will be beneficial in 
the search for vaccines or immune-therapies to liver diseases.  
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Chapter 2 – Liver Cellular immune activation 
 
“ There are at least [two] outcomes from intrahepatic T cell activation that may damage 
the liver rather than result in the graveyard death of cells and tolerance. First, the liver 
may preferentially induce low-avidity T cells that allow the persistence of viral infections 
resulting in antigen- specific chronic hepatitis. Second, T cell activation may result in a 
non-antigen-specific hepatitis through cytokine release, a not uncommon event in non-
hepatotropic viral infections.” - Doherty P. et al. June 2007. 
 
 
2.1 Introduction to liver cellular immune priming 
 
 
The key feature of adaptive immunity underpinning the basis of immunization is the 
ability of the immune system to mount a specific response against a particular pathogen 
leading to induction of long-lived memory cells that are capable of immune clearance and 
protection upon re-infection (Ahmed and Gray, 1996; Kalia et al., 2006). The original 
concept was that naïve adaptive immune cells are activated when they meet a 
professional antigen-presenting cell (APC) bearing their specific antigen (Ag) in the 
secondary lymphoid organs (Germain et al., 2012; Stremmel et al., 2006). Secondary 
lymphoid organs have highly organized structures and compartments allowing for the 
concentration of lymphocytes; which in turn enhances the access of APCs to specialized 
B and T cells for the initiation of adaptive immunity, involving activation, proliferation 
and expansion (Beltman et al., 2007; Figge et al., 2008; Linderman et al., 2010), and 
subsequent development of protective memory cells (in the absence of chronic infection). 
This theory makes lymph nodes and other lymphoid organs the most important tissues in 
the induction of adaptive immune responses and the generation of immune memory. 
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However, this view has recently been expanded in the cellular adaptive response setting. 
A number of independent groups have shown that T cells can not only be activated in the 
absence of conventional lymphoid organs by using the liver as a substitute site, but these 
T cells can also recognize liver cells such as Kupffer, sinusoidal endothelial cells 
(LSECs), hepatic stellate and even hepatocytes as APCs when they express the cognate 
Ag specific for that T cell (Bertolino et al., 1998; Crispe, 2011; Derkow et al., 2011; 
Hofmann et al., 2010; Lukens et al., 2009; Wuensch et al., 2010). Transgenic mice 
lacking lymph nodes and Peyer’s patches showing alterations to other secondary 
lymphoid organs such as spleen and thymus due to point mutations in NFκ-B were 
immunodeficient. However, a group from Switzerland reported that the 
immunodeficiency exhibited by these mice was not from the modification or the total 
lack of the secondary lymphoid structures but rather, a defect in cellular immune 
activation. The group depicted an unconventional pathway from which an APC can 
sample antigen and present it to a newly formed lymphocyte in the liver. This process 
was adequate in inducing cell mediated immune (CMI) responses but not antibody 
mediated immune response (Greter et al., 2009). In all, these independent groups provide 
evidence that liver can not only act as a reservoir for the activation of certain naïve 
adaptive cells but also can present these antigens to the adaptive cells like an APC.  
Despite this newfound knowledge, it is known that for hepatotropic infections such as 
Hepatitis B, Hepatitis C and malaria, there are clear impairments in cell-mediated 
immunity (CMI). The defect in T cell immune response has been largely credited to the 
impairment in pathogen resolution and T cell exhaustion, which leads to the 
establishment of chronic infection (Folgori et al., 2006; Guocai Lv, 2010; Struik and 
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Riley, 2004). Efforts directed towards the development of therapeutic vaccines against 
these pathogens have yet to yield fruitful results. Therefore, it is important to take a step 
back and evaluate the factors that are negatively affecting the induction of strong immune 
responses against liver-tropic pathogens, which may prove critical for the development of 
effective immune-therapies.   
 
2. 2 Transfecting the liver – Hydrodynamic Injection  
 
2.2.1 Hydrodynamic Injection model 
 
Primary CD8 T cell activation by liver APCs has been described by several independent 
groups with both in vivo and in vitro models (Bertolino et al., 2001; Bertolino et al., 
1998; Crispe, 2011). Until now, the fate of CD8 T cells primed in the liver has been a 
subject of controversy in efforts to explain the failure of immunity in chronic liver 
infections such as HBV, HCV and malaria. Groups using transgenic mice that express 
antigen in the liver believe T cells undergo rapid Bim-dependent apoptotic death 
immediately after activation in the liver or by liver cells. Bertolino et al, explains that 
naïve CD8 T cells which obtained antigens in the liver through liver cells up modulate a 
specific apoptotic marker known as Bcl-2-interacting mediator of cell death, which 
initiates apoptosis in the activated CD8 T cells (Bertolino et al., 1999; Holz et al., 2008; 
Holz et al.).  Other groups, who used viral vectors as models to express antigen in the 
liver, immediately challenged this theory. Using viral vectors such as adenovirus (Lukens 
et al., 2009) and AAV (Wuensch et al., 2006), they implied that liver activated CD8 T 
cells undergo full differentiation with some defective anti-viral activities.  
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Although, these experiments were well designed, there were some caveats to the models, 
which encouraged a particular conclusion.  Neil et al. believe using transgenic mice that 
express a specific antigen in the liver defeats the purpose of antigen processing and 
presentation, since the antigen exists throughout the lives of the mice and therefore 
pushes the responses towards tolerance instead of immunity. The group attempted to fix 
the issue by using transplant models and viral vectors that express de novo antigens. 
These models solved the tolerance issues by inducing long-lived effector cells but 
unfortunately, represented a chronic infection model. Expression of Ag exclusively in the 
liver using the transplant and viral vector models can facilitate Ag to persist for several 
months. Therefore, it is fair to point out that these models do not represent an acute 
pathogenic infection but rather represent chronic infection models.  
To gain insight into effector differentiation and memory programming of CD8 T cells 
post liver priming, a unique model with transient Ag expression is needed. We used a 
hydrodynamic DNA plasmid injection approach to model an acute liver infection. 
Hydrodynamic injection (HI) of antigen encoded DNA has been used previously as a 
model for acute HBV and HCV infection (Yang et al., 2002). Depending on the type of 
DNA vector or promoter (Osborn, 2011), expression of the transgene can be transient or 
can persist for weeks. This hydrodynamic-based transfection normally results in the rapid 
uptake of DNA molecules into the cytosol of hepatocytes (Andrianaivo et al., 2004) with 
detectable Ag expression within hours. The Ag expression kinetics are comparable to 
what is observed in skeletal muscle after conventional intramuscular injection (Wolff, 
1992). This expression was restricted to the liver (Figure 2.1a) and lasted for only 4 
days, mimicking acute infection (Figure 2.1b). Unlike other models, the level of 
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transgene expression is likely to represent the expression of viral Ag in the liver during 
hepatotropic pathogenic infection. We utilized this model for expression of an LCMV-gp 
in mouse liver after hydrodynamically injecting the plasmid DNA vector. Expression of 
this transgene product was not seen in other major tissues (Figure 2.1a).   
 
2.2.2 P14 transgenic model  
 
LCMV glycoprotein DNA plasmids were used instead of plasmids to antigens from liver-
tropic pathogen in the hydrodynamic injection to establish infection in the liver. LCMV-
gp was used because the studies were done with chimeric NOD.Cg-
Tg(TcrLCMV)327Sdz/DvsJ (P14) transgenic mice. P14 mice are set of LCMV-specific 
CD8 T-cell clones from irradiated B10.BR/SgSn (H-2K) reconstituted with T-cell 
depleted C57BL/10Sn (i H-2b) bone marrow cells. These mice contain Tcrb-V8.1, TcrB-
D, TcrB-J2.4 genes, which express under the control of H-2Kb promoters (Pircher, 
1989b).  
These P14 transgenic mice have many advantages, which help us understand antigen 
specific T cell activation. Since almost all cytotoxic T cells in these mice are specific to 
one epitope, there’s high frequency of activated CD8 T cells after antigen expression. 
The high frequency of T cells facilitates phenotypic analysis on a per cell basis. It also 
eliminates the need for ex vivo stimulation of cells, which induces measurable immune 
cytokines after DNA or peptide vaccine immunizations. More importantly, these mice 
represent different congenic strains (Thy1.1 or Ly5.1) from regular black 6 mice (Thy1.2 
or Ly5.2), which make it easier to stain and analyze cells without using expensive 
tetramer antibodies.  
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Figure 2-1 
 
Hydrodynamic Injection acutely transfects the liver 
a.  
 
 
 
b.  
 
 
FIGURE 2-1. Hydrodynamic Injection acutely transfects the liver. Mice 
hydrodynamically injected with LCMV-gp mutant DNA expressed antigen exclusively in 
the liver. (A) Immunohistochemistry staining of the transgene product in tissue sections 
24 hours post-injection with LCMV-gp mutant plasmid. Results represent brain, heart, 
intestine, kidney, liver, lymph node, lung, muscle, spleen, and skin. (B) Time course (in 
hours) of transgene transduction efficiency in mouse liver. 
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2.3 Intrahepatic CD8 T cell priming, proliferation, expansion, 
and contraction 
 
2.3.1 Extralymphatic priming of CD8 T cells 
 
The initial priming of CD8 T cells plays a critical role in their subsequent development 
into competent functional and/or memory cells (Reinicke et al., 2009; Shedlock and 
Shen, 2003). However, there are gaps in our understanding on the influence of the liver 
compartment itself on T cell activation and effector differentiation: the initial activation, 
clonal expansion and contraction. In this study, we qualitatively and quantitatively 
compared CD8 T cells primed in either the liver or in peripheral lymphoid tissue. We 
utilized hydrodynamic injection to transiently transfect the liver of naïve P14.Thy1.1 
recipient mice with LCMV-gp transgene. Cognate antigen-expressing hepatocytes 
successfully induced activation of naïve P14 CD8 T cells (Figure 2.2a) as previously 
shown in transplant, adenovirus and AAV models (Bertolino et al., 1998; Lukens et al., 
2009; Wuensch et al., 2010).  Still, restricting Ag expression to the liver does not rule out 
the possibility that CD8 T cells were being primed in the lymph nodes by professional 
APCs that have processed liver-derived Ag. To examine if priming takes place in lymph 
nodes or elsewhere, we treated the mice with immunomodulating compound, (FTY720), 
which sequesters naïve lymphocytes in lymph nodes (Figure 2.2b), thus, preventing 
interaction with the transfected hepatocytes. The sequestering of naïve lymphocytes in 
lymph nodes averted the priming of transferred P14 TCR transgenic CD8 T cell induction 
and proliferation (Figure 2.2c). A group of naïve P14 recipient mice were also treated 
with L-selectin (CD62L) antibody prior to immunization. Consistent with previous data 
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(Lepault et al., 1994), anti-L-selectin treatment led to severe naïve T cell depletion in the 
lymph nodes (data not shown). This treatment did not change the priming of transferred 
P14 TCR transgenic CD8 T cells after intrahepatic (IH) expression of cognate antigen. 
CD8 T cell priming was documented by studies of antigen-specific proliferation and CD8 
T cell expansion (Figure 2.2c). Together, these data suggest that liver transfection 
through hydrodynamic injection encourages extralymphatic priming of the transgenic 
CD8 T cells.  
 
2.3.2 Expansion and contraction phases of Liver-primed CD8 T 
cells 
 
Although, intrahepatic primed CD8 T cells are known to differentiate into effector cells, 
it is unclear whether they undergo this transition with the same dynamics and phenotypic 
changes that occur during the naïve-effector transition of CD8 T cells during acute viral 
infection (Wherry and Ahmed, 2004). Here, we compared the hydrodynamic intrahepatic 
injection model (IH) to intramuscular control (IM), which achieves T cell induction 
through Ag presentation within its associated lymph nodes.  
Five days following the initial immunization, Ag-specific CD8 T cells were detectable 
using DbGP33 tetramer in blood for both groups, indicating successful priming at both 
sites. CFSE labeled adoptively transferred cells in IH model exhibited quicker 
homeostatic proliferation during the first week of immunization, in peripheral lymph 
nodes (PLN) and spleen (SPL) as compared to the IM control model (Figure 2.3a). 
Proliferation in non-lymphoid tissues such as liver (LIV) and lung (LUN) at day 7 was 
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however, comparable between the two groups. Antigen specific CD8 T cell proliferation 
in all tissues averaged around 98% two weeks post immunization. Next, we examined the 
expression levels of different activation markers: CD25 and CD44, and CD62L following 
CD8 priming in both models. We observed a significant increase in CD25 and CD44 
expression on Thy1.1 CD8 T cells of IH mice in all tissues at day 7 and 14 post infection 
(Figure 2.3b).  In addition, down-regulation of CD62L, which is usually seen in effector 
CD8 T cells, was only visible 14 days post infection.  However there was no difference in 
the expression levels of these activation markers between the IH model and the IM 
control group. 
Expansion and contraction are two of the three characteristics reported when CD8 T cells 
are primed in a conventional setting. However, the kinetics of these two phases has not 
been detailed with regard to lymphoid tissue-independent activation models. We explored 
the frequency of CD8 T cell responses induced by IH in contrast to those induced by IM. 
Following immunization, T cell expansion from IH rapidly peaked on day 6 with 0.7% of 
Ag-specific cells detected in the blood. This early expansion was followed by a rapid 
contraction phase. At day 9 post-infection, 57% of the Ag-specific cells were already 
dead and the percent contraction increased to 82% by week 2. In the IM control group, 
only 0.2% Ag-specific cells were detected on day 6 (Figure 2.3c). However, an increase 
in Ag-specific CD8 T cells (to ~4.2%) was observed at day 15 post-infection.  
Furthermore, the Ag-specific CD8 T cells in IM control group underwent a gradual 
contraction over the next 3 weeks.  
To evaluate the tissue distribution of Ag-specific cells in lymphoid (spleen and lymph 
nodes) and non-lymphoid tissues (liver and lung), we calculated the absolute numbers of 
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Thy1.1 cells in these tissues (Figure 2.3d-g). We observed similar expansion-contraction 
phases between groups in the tissue as observed in the blood (Figure 2.3c). Although IH 
underwent rapid and robust contraction phase after expansion, about 0.03, 0.05, 0.3 and 
0.4 percent of Ag-specific CD8 T cells were left in the lymph nodes, spleen, liver and 
lung respectively as compared to the IM control which had 0.08, 0.17, 1.6 and 1.4 percent 
cells present in the respective tissues 12 weeks after immunization (Figure 2.3g).  
 
2.3.3 Modulation of apoptotic and survival markers on liver 
primed CD8 T cells  
 
The rapid death of the primed CD8 T cells in the IH group, suggested experimentation of 
how pro-apoptotic and survival markers are regulated during both the expansion and 
contraction phase in these cells. First, we examined the modulation of Bim, a member of 
the Bcl-2 family that promotes apoptosis and is known to be up regulated in intrahepatic 
activated cells.  We observed increased Bim expression in CD8 T cells from the lymph 
nodes, liver and lungs of the IH mice during the first week of activation (Figure 2.4a). 
However, on day 14 post-immunization, Bim expression was lower in all tissues of the 
IH group when compared to the IM control. Bim expression was found to be particularly 
high on DbGP33-specific effector and host CD8 T cells in the liver. To determine if this 
increase in Bim was not due to T cell activation in the liver, Thy1.1 T cells were 
transferred into naïve Thy1.2 mice and the expression levels of Bim was monitored for 
12 days. The expression of this death marker was highest on liver-resident CD8 T cells 
when compared to cells derived from the spleen and lymph nodes (Figure 2.4b).  
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We also analyzed the regulation of the survival marker, Bcl-2, to determine when these 
cells acquire their memory phenotypes. Peak expansion of effector CD8 T cell in the IH 
group coincided with the down-regulation of Bcl-2 on day 7 post-immunization. The 
average mean fluorescence intensity (MFI) was 422, 484, and 430 in lymph nodes, spleen 
and liver respectively, while the IM control mice averaged 1009, 967, and 1086 in the 
respective tissues. Bcl-2 expression in the IH group was higher than that of the IM group 
on week 2, which represents the peak of expansion for lymphoid-dependent CD8 T cell 
priming. The MFI of 662 in lymph nodes, 583 in spleen and 832 in liver, indicated there 
was increased expression of Bcl-2 in the IH group as compared to the control IM group 
(480 in lymph node, 493 in spleen and 349 in the liver). This enhancement was even 
more significant by day 21, where the average MFI was 1326, 667, 490 for IH and 509, 
290, 349 for IM groups (Figure 2.4c). These data confirm that cells primed outside 
lymphoid tissues in the liver up-regulate death signals while down-regulating survival 
signals at earlier time points, a phenotype which is reversed at later time periods post 
immunization.  
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Figure 2-2 
 
Intrahepatic CD8 T cell activation  
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Figure 2-2 cont.  
 
b.  
 
c.  
 
FIGURE 2-2. Intrahepatic CD8 T cell activation. Hydrodynamically injected mice 
expressed antigen in the liver and eventually induced CD8 T cell activation. (A) The CD8 
T cell priming was evident by the expansion of Thy1.1 P14 CD8 T cells and upregulation 
of CD44 activation marker. The expansion and increase in CD44 in the intrahepatic 
group was comparable to that of intramuscular control group.  (B) Treatment with 
FTY720, an immunosuppressive drug that sequesters circulating lymphocytes in lymph 
nodes. The percent lymphocytes and total naïve CD8 T cells drastically reduced in the 
liver after FTY720 treatment.  (C) The treatment abrogated antigen specific CD8 T cell 
activation. However, preventing lymph node entry of naïve lymphocytes using anti-
CD62L had no effect on DbGP33+specific CD8 T cell induction.  
82% 85% 
2.6% 55% 
SS
C-
A 
CD8 
5.4 x 105 4.6 x 105 
1.2 x 103 7.8 x 104 
FTY720 treated Untreated 
Lymph Nodes 
Liver 
Unimmunized Immunized FTY720 treated α-CD62L treated 
C
D
90
.1
  
CFSE 
 29 
Figure 2-3 
 
Expansion and contraction of liver primed DbGP33+specific 
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Figure 2-3 cont.  
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Figure 2-3 cont.  
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Figure 2-3 cont.  
 
 
 
 
g.  
 
 
 
 
 
FIGURE 2-3. Early expansion and contraction of liver primed DbGP33+specific CD8 
T cells. CFSE-labeled CD8 T cells isolated from lymphoid and non-lymphoid organs of 
mice either expressing either Ag intrahepatically (IH) or intramuscularly (IM) were 
analyzed at indicated time points. (A) Proliferative capacity and (B) expression of 
important activation markers on transferred DbGP33+specific CD8 T cells. Frequency 
kinetics of the of GP33-specific CD8 T cell response in (C) PBMC, (D-G) lymph nodes, 
spleen, liver, and lung following immunization. 
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Figure 2-4 
 
Modulation of different apoptosis regulator proteins 
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Figure 2-4 cont.  
 
c. 
 
 
 
 
 
 
 
 
FIGURE 2-4. Modulation of different apoptosis regulator proteins during the 
expansion and contraction phases of liver-primed CD8 T cells. (A) Early upregulation 
of the pro-apoptotic marker, Bim, was observed in the activated CD8 T cells of the IH 
group at their peak of expansion. Increased Bim expression was seen on both activated 
and (B) naïve Thy1.1 cells isolated from different tissues demonstrate different levels of 
Bim expressions.  (C) Survival signal, Bcl-2, expression was conversely correlated to that 
of Bim.  
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2.4 Effector and memory differentiation 
 
The ultimate goal of the anti-viral immune response is to generate strong effector cells to 
clear infection along with long lasting memory CD8 T cells, which will quickly respond 
to subsequent infections. Recent studies have provided a phenotypic profile for a subset 
of effector CD8 T cells that will commit to become memory T cells(Amoah et al., 2012).  
Cells within a polyclonal response can be grouped into short-lived effector cells (SLEC) 
and memory precursor effector cells (MPEC) based on the expression levels of the killer 
cell marker, KLRG1 among many surface markers (Figure 2.5a). This description is well 
established for CD8 T cells that are primed within the lymph nodes but not for 
intrahepatic primed CD8 T cells. We next confirmed that CD8 T cells primed outside the 
SLT have the capacity to differentiate into SLEC and MPEC (Figure 2.5a and 2.5b). 
The liver-primed CD8 T cells in the blood, however, acquire more SLEC subsets early 
while the MPEC subset increases only 12 days post immunization, when the SLEC begin 
to die off. This increase of MPEC in the IH group at day 12, contrasts with that of the IM 
immunized group where a similar trend was seen in both lymphoid and non-lymphoid 
tissues. We observed early increases in KLRGhi cells in the IH immunized group for each 
individual tissue (Figure 2.5c). Although these markers allowed us to identify cells 
within the liver-primed CD8 T cell population that have the potential to become memory 
cells, it was not clear if they actually became memory CD8 T cells. Using CD44, IL-7Rα 
and L-selectin, we categorized the Thy1.1 cells into effector, effector memory and central 
memory CD8 T cells (Figure 2.5d). Flow cytometric analysis of CD8 T cells from the 
lymph nodes, spleen and liver on days 21 and 84, indicated similar distribution of effector 
and memory cells between the IH and IM groups. The intrahepatic primed CD8 T cells, 
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however, up-regulated both IL-7Rα and L-selectin (central memory) earlier than the 
lymphoid primed CD8 T cells (Figure 2.5e). Although liver-primed CD8 T cells 
differentiate into memory cells more quickly than lymphoid primed cells, the distribution 
of effector, effector-memory and central memory cells were similar in all tissues within 
the groups. Crispe et al, believe that direct liver priming of CD8 T cells promotes the 
expression of inhibitory molecules such as PD-1(Wuensch et al., 2010). We did not 
observe a significant increase in PD-1 expression for the IH group. The liver 
microenvironment seems to up-regulate PD-1 on both naïve and effector cells, regardless 
of the priming site (Figure 2.6a). Naïve Thy1.1 cells transferred into unimmunized 
Thy1.2 recipients maintained a higher level PD-1 expression in the liver compared to 
spleen and lymph node over a period of time (Figure 2.6b). Additionally, HBV 
persistence in mice has been shown to increase PD-1 expressing CD8 T cells in liver 
infiltrating lymphocytes(Tzeng et al., 2012).  Thus, the increase expression of PD-1 on 
memory CD8 T cells after intrahepatic activation in their model may be a consequence of 
the continued Ag expression in the liver and not an undesirable effect from liver-priming.  
These studies support that liver-primed P14 CD8 T cells can divide and express 
activation and memory markers, but it is still important to examine if these CD8 T cells 
can induce antiviral activity in response to antigenic re-encounter. To assess this, we 
evaluated the ability of Ag-specific CD8 T cells elicited by hydrodynamic injection to 
produce antiviral cytokines including IFN-γ, TNF-α and IL-2, in response to LCMV-
GP33 peptide stimulation in vitro (Figure 2.7a). About 50, 55 and 13 percent of CD8 T 
cells from the lymph nodes of the IH group produced IFN-γ, TNF-α or IL-2 respectively 
in this assay. These numbers were higher for spleen, where 77, 67 and 30 percent of CD8 
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T cells produced the above-mentioned ctykines, while the liver primed showed lower 
cytokine production at 44, 59 and 7.8 percent respectively. However, only 44, 59 and 7.8 
percent of CD8 T cells in the liver produced IFN-γ, TNF-α or IL-2, respectively. By 
contrast, a higher percent of lymphoid-primed CD8 T cells produced these cytokines. For 
example, 93, 93 and 45 percent of CD8 T cells from the spleen of the IM control group 
produced IFN-γ, TNF-α or IL-2 respectively. 
Further, current data suggests that poly-functionality i.e, the ability of single cells to 
produce multiple cytokines, is one of the essential functional properties of long-lived 
memory cells. Indeed, similarities in poly-functionality of CD8 T cells derived from the 
liver and spleen were observed between the two groups. However, cells from the lymph 
nodes of the IH group were significantly less functional than those of the IM group 
(Figure 2.7b). 
 
 
 
 
 
 
 
 
 
 
Figure 2-5 
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Effector and memory differentiation of liver-primed T cells. 
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FIGURE 2.5. Effector and memory differentiation of liver-primed CD8 T cells. (A) 
Phenotypic profiling of effector intrahepatic-activated GP33-specific CD8 T cell subsets 
with distinct memory fates. Expansion and contraction of short-lived effector cells 
(SLEC) and memory precursor effector cells (MPEC) in (B) PBMC and (C) other 
lymphoid and non-lymphoid tissues. (D-E) Distribution of effector and memory CD8 T 
cells from IH and IM immunized mice at days 21 and 84 post-infection.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-6 
IH IM 
PLN SPL 
IH IM IH IM 
LIV 
Pe
rc
en
t 
Day 84 
0
20
40
60
80
100
0
20
40
60
80
100
0
20
40
60
80
100
 45 
 
The expression of PD-1 on DbGP33+specific CD8 T cells 
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b.  
 
 
 
 
 
 
 
 
 
FIGURE 2.6. The expression of PD-1 on DbGP33+specific CD8 T cells.  While there 
was no significant differences in the expression of the negative regulator marker (PD-1) 
between the (A) IH and IM immunized groups, (B) there were differences in expression 
on naïve CD8 T cells between the liver, lymph nodes and spleen.   
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Magnitude and polyfunctional profile of GP33-specific CD8 T 
cell responses 
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FIGURE 2.7. Magnitude and polyfunctional profile of GP33-specific CD8 T cell 
responses.  The ability of liver-primed CD8 T cells to produce cytokines, IFN-γ, TNF-α 
and IL-2 following in vivo stimulation with synthetic peptide was analyzed. (A) A 
representative flow chart showing single cytokine producing cells and (B) an IFN-γ 
positive cells were analyzed for their ability to co-produce TNF-α and IL-2 (pie chart).  
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In addition to antiviral cytokine production, a crucial function of effector CD8 T cells is 
induction of cytotoxicity.  Accordingly, we used an in vivo cytotoxicity assay to assess 
the whether STL-independent primed CD8 T cells become effective CTLs. One week 
after immunization, during which the peak of expansion occurs, we examined the killing 
of transferred target cells pulsed with either LCMV-GP33 peptide or LCMV-NP 
(control). Twenty-four hours after transfer of target cells, about 88% of LCMV-GP33 
pulsed target cells were eliminated in the blood of the IH group, while only 76% of the 
target cells were killed in the IM group. However, when target cells were transferred 3 
weeks post immunization, where 0.15% Ag-specific CD8 T cells can be detected in the 
spleen of the IH group (compared to 1.5% of the IM group), only 2% of the relevant 
antigen pulsed target cells were eliminated. This is in sharp contrast to the IM group, 
which killed about 75% of the target cells (Figure 2.8a). We allowed the transferred 
target cells to reside in the recipient mice for 72 hours but did not see any improvement 
in killing (Figure 2.8b). This lack of cytolytic activity was also observed in the lymph 
nodes, spleen, liver and lung, indicating that the effector CD8 T cells were not selectively 
sequestered in any particular tissue Figure 2.8c). Furthermore, we stained the antigen-
specific CD8 T cells for degranulation markers, granzyme B and CD107a, to verify 
whether they were still effective CTLs. The Ag-specific memory CD8 T cells primed in 
the liver were capable of inducing these degranulation markers following antigen 
stimulation (Figure 2.8e). To confirm that the lack of target cell elimination in the IH 
group is not due to defective liver-primed memory CD8 T cells, we transferred 3.5 x 104 
antigen specific cells from each group into naïve mice and evaluated their cytolytic 
 50 
activity in the recipient mice. Interestingly, none of the recipient groups were able to 
eliminate the peptide pulsed target cells (Figure 2.8d) 
At least 4-6 weeks following the immunization, mice were challenged with 200 PFU of 
LCMV Arm- strong by the intracranial (I.C) route. Figure 2.9 displays the data from the 
challenge study and survival for each group of mice. While the IM immunization yielded 
80% protection, all naïve mice and IH vaccinated animals succumbed to infection.  
This lack of killing was associated with the low frequency of effector-memory cells in the 
IH group. Although, the IH group’s memory precursors comprise about 16% of peak 
effector cells in the IH group, the frequency was still very low due to its lower effector 
frequency. As predicted, hydrodynamic immunized mice repeatedly succumbed to lethal 
dose LCMV i.c challenge.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-8 
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CTL-mediated cytotoxicity of liver-primed effector and 
memory CD8 T cells 
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c.   
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d.  
 
 
e.  
 
 
FIGURE 2.8. CTL-mediated cytotoxicity of liver-primed effector and memory CD8 
T cells. (A-B) Intrahepatic activated GP33-specific CD8 T cells display rapid cytolytic 
activity during the first week of activation but this ability to specifically remove antigen-
pulsed target cells in vivo diminished before day 21.  (C) Percent in vivo killing in the 
spleen, lymph nodes, liver, and lung for IH and IM mice at week 3 post-immunization. 
(D) Cytolytic activity in the spleen of naïve mice that have respectively received equal 
frequencies (30,000) of activated DbGP33+specific CD8 T cell from IH and IM 
immunized mice. (E) The antigen-specific degranulation assay. Splenocytes from both 
groups (IH and IM) were stimulated ex vivo with LCMV-gp peptides in the presence of 
CD107a antibody. The stimulated splenocytes were subsequently stained with anti-
Granzyme B (Gzm B).  
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Protective immunity in hydrodynamically injected mice 
 
 
 
 
 
FIGURE 2.9. Protective immunity in hydrodynamically injected mice. Thirty days 
after immunization, groups of naïve, hydrodynamically injected and intramuscularly 
immunized mice were challenged with lethal dose of LCMV by i.c. infection (n= 10-15 
mice/group). Following i.c. infection, mice were monitored for mortality.  
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2.6 Conclusions 
  
 
Hepatotropic pathogens, such as HBV and HCV, often escape cellular immune clearance 
resulting in chronic infection.  The mechanisms by which liver primed CD8 T cells 
become defective is not clearly understood.  In this report, we directly compared liver 
primed CD8 T cells to secondary lymphoid tissue primed CD8 T cells for differentiation, 
function, and memory programming in a highly controlled fashion. We used 
hydrodynamic tail vain injection of plasmid to establish a liver-specific LCMV-gp 
antigen transient expression, and studied priming of CD8 T cells using the P14 transgenic 
mouse model. Intrahepatically activated CD8 T cells exhibited unique expansion, 
memory differentiation, polyfunctionality and cytotoxicity compared to T cells primed in 
the periphery. We reported an unexpected defect in the initial induction of adaptive 
immune response following viral antigen expression and a non-inflammatory priming of 
CD8 T cells in the liver. Priming of naïve CD8 T cells in the liver compromises the cells’ 
expansion capacity, eliciting a 3 to 500-fold decrease of effector cell frequency and 2 to 
9-fold decrease of memory CD8 T cell frequency in multiple tissues. Although liver 
priming resulted in early effector differentiation, the overall quality of the effector 
functions: polyfunctionality and cytotoxicity, were somewhat comparable to CD8 T cells 
primed in lymphoid tissues. The memory cells’ poor antigenic clearance and viral control 
illustrate their low CTL frequency.  
In summary, these results provide evidence that the lack of recall response needed to 
protect mice from secondary challenge after liver-priming of CD8 T cells, is directly 
associated with a defect in the initial clonal expansion. In human studies, the lack of viral 
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clearance in chronic HBV and HCV infections, correlates with the low number of HBV 
or HCV-specific CD8 T cells detected in the blood(Sobao et al., 2001; Sobao et al., 
2002). Although, further studies are needed, we theorize that liver CD8 T cell priming 
during hepatotropic pathogen infection likely contributes to the low frequency of Ag-
specific CTLs seen in chronic infections.  
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Chapter 3 – Therapeutic hepatitis B vaccine 
 
“ It was a very, very exciting time… But I really wasn’t trying to develop a vaccine. 
Actually, all we did in our little laboratory, our little kitchen, so to speak was boil 
hepatitis B serum and water” – Saul Krugman, medical researcher.  
 
3.1 Introduction to hepatitis B vaccines 
 
The previous chapter showed that intramuscular immunization, combined with 
electroporation, can drive antigen-specific cell mediated immune response in the liver 
when mice were vaccinated with plasmids encoding parts of the LCMV genome. While 
the LCMV serves as an effective model for studying the dynamics of CD8 T cells in the 
liver, the virus is however not a natural hepatotropic pathogen. LCMV is also a rodent-
borne viral infection with little clinical importance. A vaccination approach that drives 
immune response in the liver is important in developing therapeutic immunotherapy for 
hepatotropic pathogens such as hepatitis B and C virus, and malaria plasmodium. We 
elected HBV as a model to study this immunization approaches for reasons described 
below.  
Hepatitis B is the only pathogen out of the three successful human liver pathogens to 
have an effective vaccine. The vaccine has been used to prevent the infection of HBV in 
billions of people across the globe and remains as one of the most successful prevention 
tools for any human viral infection.  Despite the effectiveness of the current hepatitis B 
vaccine, two billion people have already been infected with the virus and 370 million of 
that group is currently living with chronic HBV. These chronically HBV-infected 
individuals are at risk of liver cirrhosis and cancer. Over a million chronically infected 
patients die each year from liver complications or liver cancer(Iloeje et al., 2012; 
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Lavanchy, 2004).  The therapies available to treat HBV infection are effective for viral 
control but costly. The cost of treatment according to WHO can range from $20,000 to 
$40,000 annually, depending on the stage of the liver disease. Since current therapy only 
controls replication and does not clear infection, there is a major need for new 
approaches. These costs do not include the frequent hospitalizations or liver 
transplantation (over $90,000), needed at the end stage of the liver disease (Metcalf et al., 
1999; Wong et al., 1995). This substantial economic burden is not only a predicament for 
the infected individuals but for nations around the world. Many infected individuals 
require assistance from government programs. Indirect costs attributable to lost workdays 
and lost productivity are also enormous. Most people who can afford treatment benefit 
very little from it, as only about 30% respond to the common interferon-α therapy. 
Response to treatments also differs between genotypes. There are many undesirable 
effects with current therapies which range from myalgia, fatigue, arthralgia, insomnia, 
diarrhea, depression, anorexia, erythema, dyspepsia, leucopenia, alopecia, rhinitis, 
vomiting, dysmenorrheal, hypertriglyceridemia and pruritus to psychological 
abnormalities (Sleijfer et al., 2005).  
These issues support the need for therapeutic vaccines for both acute and chronic HBV 
infections. The ideal goal is to develop a vaccine that is capable of clearing the virus and 
leaving protective antibodies and T cells. The previous HBV vaccines have been 
effective as prophylactics but not so much as therapeutic vaccines. Since the current 
vaccine platform does not support the induction of antiviral CD8 T cell responses capable 
of clearing infected hepatocytes.  
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3.2 Hepatitis B vaccine history and current approaches 
 
3.2.1 Making hepatitis B vaccine  
 
In the late-1960s, Saul Krugman, a professor of pediatrics at the New York University 
School of Medicine performed what is considered one of the most unethical studies in the 
history of medicine. The findings from this study however became one of the biggest 
breakthroughs in modern medicine. The end result was the innovation of a vaccine that 
will over the years save billions of lives.  
Baruch Blumberg (Blumberg, 2002; Das, 2002) and Alfred Prince (Ganem and Prince, 
2004) initiated studies of HBV when the virus was virtually unknown to almost all 
virologists. Blumberg found that 1 in every 20 Americans have antibodies to a novel 
protein he discovered in the blood of an Australian Aborigine. He named this protein the 
“Australian antigen” (later found to be hepatitis B surface antigen). Although Blumberg 
linked this protein with different diseases, it wasn’t until Alfred Prince’s studies with 
blood transfusion patients Showed that the protein was part of the hepatitis B virus. 
Baruch Blumberg went on to win a Noble Price a decade later for this discovery. 
Following the footsteps of Blumberg and Prince, Saul Krugman made an effort to 
understand these particles (proteins) in the blood of the infected individuals and to see if 
the infectious particles (virus) were also present in the blood. He injected high-risk 
mentally challenged children with blood collected from infected patients. Almost all the 
children became sick, which led him to conclude that the hepatitis B virus is also present 
in the blood.  With Krugman’s knowledge on Blumberg’s studies, which shows that some 
Americans have antibodies to the “Australian antigen”, Krugman believed that if he 
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could somehow transfer the “Australian antigen” into the mentally challenged children, 
he might be able to generate similar and hopefully protective antibodies.  And so he did. 
Cooking serum containing hepatitis B vaccine almost to the boiling point of water, he 
was able to inactivate the infectious properties of the virus and able to protect injected 
children from subsequent infection. This led to the development of a Hepatitis B vaccine 
(Krugman S, 1984; Sherlock, 1984) (Best and Neuhauser, 2010; Sherlock, 1984).  
Although, Krugman did not want to call it a vaccine, Maurice Hilleman, the head of 
vaccine research at Merck, believed it was. Dr. Hilleman, who developed many important 
vaccines against deadly diseases including mumps, rubella and measles, was looking to 
develop a vaccine against hepatitis B when he came across Krugman’s data. Hillman 
collected blood from homosexual men from New York (who were believed to be at risk 
for blood transmitted diseases like hepatitis B), filtered and concentrated the samples, and 
treated them with pepsin, urea and formaldehyde.to destroy potential particles. This 
sequence of treatments was sufficient enough to kill every known virus he tested (Human 
Immunodeficiency Virus (HIV) was unknown then) but it left some hepatitis B surface 
antigen. Hillman then filtered the product to get purified surface antigen. This was 
delivered into people as the first hepatitis B vaccine. Many controversies surrounded the 
use of blood-derived vaccines as both scientists and the public had concerns over safety. 
These controversies intensified when HIV was discovered. HIV was also found to be a 
blood-transmitted virus and was known to be prevalent in homosexuals. This led to 
withdrawal of Krugman/Hillman hepatitis B vaccine from the market and the 
development of recombinant hepatitis B vaccine, commonly known as second generation 
hepatitis B vaccine (Hilleman, 2003; Offit, 2008).  
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3.2.2 Second-generation hepatitis B vaccine  
 
Pablo Valenzuale, a Chilean biochemist, seized the opportunity to replace the blood-
derived hepatitis B vaccine with a safer option in 1986. He inserted the genes of the 
Australian antigen into Saccharomyces cerevisiae (yeast) and harvested the noninfectious 
protein and used it as a vaccine. This vaccine was free of blood proteins or any particles 
from other pathogens. Through this method, Valenzuale and his group developed the first 
recombinant vaccine. This recombinant hepatitis B vaccine is used globally today as part 
of the World Health Organization (WHO) pentavalent vaccines (diphtheria, tetanus, 
pertussis and Haemophius influenzae type B) routine immunization program (Santos-
Lima et al.). People with levels of antibodies to the surface antigen (anti-HBs) greater 
than 100 IU/L after 3 dosages are considered good responders and normally are protected 
from HBV infection. Weak responders with anti-HBs between 10 IU/L and 100 IU/L are 
usually given another boost to help induce protection (Gilca et al., 2013) (Dervisoglu et 
al., 2011). The vaccine is believed to provide protection for a period of 10 years. 
However, current studies showed that the vaccine might provide life long protection. 
There have been a few safety concerns with this vaccine. Although some studies have 
suggested increased in risk of Multiple Sclerosis (MS) (Löbermann et al., 2010). CNS 
demyelinating (Martínez-Sernández V. Figueiras, 2012) and chronic fatigue syndrome 
(Nancy and Shoenfeld, 2008), many scientists and the World Health Organization have 
criticized most of these studies for their scientific accuracy and there remains no 
substantial evidence to confirm these safety concerns. 
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Although recombinant hepatitis B vaccine is relatively safe and induces strong protection 
in about 90% of the vaccinated population, there are several limitations the vaccine faces 
when it is used as a therapeutic vaccine.  
Like most recombinant protein vaccines, the hepatitis B vaccine lacks the ability to drive 
strong Th1 responses. Even when it is supplemented with adjuvants that help drive Th1 
responses, proteins still do not initiate the class I pathway and therefore do not generate 
CTLs. Simply neutralizing the virus with anti-HBs is not enough. T cell responses are 
needed to clear infected cells in chronically infected individuals. CD8+ T cells are known 
to be the main effector cells responsible for acute HBV clearance through both cytolytic 
and non-cytolytic pathways, induced by the production of cytokines such as IFN-γ+, 
TNF-α+. This shows that a therapeutic HBV vaccine should be on a vaccine platform that 
drives a better cellular immune response. The current vaccine also only targets the 
surface antigen of the virus. Many HBV vaccinologists believe the difference in 
protection of the current vaccine is due to the genetic divergence that often emerges from 
mutations within the surface antigens. Moreover, studies characterizing the core antigen 
(HBcAg) as the major viral determinant of HBV persistence and showing that CTL 
responses to the core protein appear undetectable, as patients ability to generate IFN-γ+  
positive T cells becomes diminished following chronic infection proves that immune 
therapies to HBV requires the HBcAg as part of the target antigens.  
Lastly, the current vaccine requires several in vitro molecular manipulations and 
production at large scale in yeast or CHO cells. This is a relatively expensive technique 
and therefore increases the market price for these vaccines. Stability is also an issue with 
recombinant protein vaccines.  
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With the hope of solving these shortcomings and developing a therapeutic approach, we 
selected the DNA vaccine platform.  
3.2.3 DNA vaccines  
 
In the early 1980’s, Dubensky and his group showed that plasmid DNA can transfect 
cells and express the needed protein in vivo after injecting mice (Dubensky et al., 1984). 
Several groups followed up and used this technique as a vaccine platform (Fynan et al., 
1993; Tang, 1992; Ulmer, 11993; Wang et al., 1993). This vaccine technology has 
remained relevant for over three decades, with several promising results. Studies in small 
animal models and non-human primates with different antigens (from different 
pathogens) have produced great levels of immunity and protection. Unfortunately, this 
level of immunity has not been well translated in human studies. Although no DNA 
vaccine is commercially available for human use, several licensed DNA vaccine animal 
products are available in the market (Table 3.1) 
Despite the inability of this vaccine technique to yield favorable protection in clinical 
studies, it continues to be a suitable platform in pre-clinical studies due to the many 
conceptual advantages it holds over other conventional vaccines.  
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Safety: Unlike live attenuated vaccines, DNA vaccines are incapable of reverting to 
virulence. They are also free from pathogenic contamination, which is an issue with 
blood-derived antigen vaccines like the first generation HBV vaccine.  
Antigen presentation: Proteins encoded by transfected DNA plasmids can be processed 
by both MHC class I and class II. This means that DNA vaccines can drive both Th1 and 
Th2 and CD8 responses, unlike recombinant proteins that only drives Th2 responses.  
Vector neutralization: The major problem with viral vectors as antigen carriers is that the 
host induces neutralizing antibodies to the vectors and makes subsequent boosting very 
difficult. This is not the case for DNA vaccines.  
Production: DNA vaccines are relatively easy to make and manipulate in large quantities 
compared to recombinant proteins and viral vectors.  
Stability: Plasmids are very stable. They can be stored or shipped at room temperature for 
a period of six months. This rules out the need for a cold chain for transport, making it 
the ideal platform for vaccines being produced in developing countries.  
In vivo translation: The expression of proteins (translation and post-translation) in multi-
cell organisms with DNA plasmids guarantees an end product that is more likely to 
resemble the native protein. It also prevents processing and presentation of unwanted 
bacterial proteins.  
Cost effectiveness: These vaccines are relatively cheap to produce when compared to live 
attenuated, recombinant protein and viral vector vaccines.  
There are few disadvantages to DNA vaccination by traditional intramuscular 
immunization:  
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Low antibody response: This immunization technique is believed to induce low levels of 
soluble antigens, which averts the stimulation of strong humoral immune responses. 
Boosting with recombinant proteins seems to rectify this inadequacy (Luo et al., 2012). 
Tolerance: Since genes are transcribe and translated in vivo, there is a possibility that the 
host immune cells will recognize these antigens as self-proteins. To avoid tolerance, 
proteins have to be expressed at high levels.  
Upsetting host gene transcription: Transfecting cells with DNA plasmids can cause 
changes in gene regulation in host cells.  
Ineffective for non-protein antigen: This technique is not very useful for pathogens that 
incite immune responses using non-protein antigens such as polysaccharides.  
 Overall, the many advantages of DNA vaccination override these shortcomings.  
These disadvantages can also be corrected with different immunization techniques and 
the use of adjuvants.  
The exact mechanism by which DNA vaccination induces an immune response is not 
fully understood, However, it is speculated that local antigen-presenting cells are directly 
transfected or can acquire antigens through the secretion of antigen from transfected 
myocytes(Hokey and Weiner, 2006) for subsequent processing and presentation these 
antigens to resting lymphocytes in secondary lymphoid organs (Figure 3.1)  
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Table 3-1 
 
Licensed DNA vaccine therapies 
 
 
 
 
Company  
name 
 
 
 
Vaccine 
name 
 
 
 
Vaccine 
target 
 
 
 
Target 
animal 
 
 
 
Licensed 
date 
 
 
 
Reference 
 
 
Centers for 
Disease Control 
and Prevention 
and Fort Dodge 
Laboratories 
 
 
 
 
 
 
West Nile 
Innovator 
 
 
 
 
West Nile 
virus 
 
 
 
 
Horses 
 
 
 
 
2005 
 
 
 
 
(Davidson 
AH, 2005) 
 
 
 
Novartis 
 
 
 
 
 
Apex-IHN 
 
 
Infectious 
haematopoietic 
necrosis virus 
 
 
 
 
 
Salmon 
 
 
 
2005 
 
 
 
(Greter et 
al., 2009) 
 
 
 
VGX Animal 
Health 
 
 
 
 
 
LifeTide-
SW5 
 
 
Growth 
hormone 
releasing 
hormone 
 
 
 
Pig 
 
 
 
2007 
 
 
 
(Kutzler 
MA, 2008) 
Merial, 
Memorial 
Sloan–Kettering 
Cancer Center 
and The Animal 
Medical Center 
of New York 
 
 
Canine 
Melanoma 
Vaccine 
 
 
 
Melanoma 
 
 
 
Dogs 
 
 
 
2007 
 
 
(Bergman 
et al., 
2006) 
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  3.2.3 Improving the DNA vaccine technology  
 
As mentioned earlier, a key challenge in DNA vaccines field at the moment is poor 
immunogenicity in larger animals and humans. In small animals, DNA vaccine induce 
less antibody responses when compared to other vaccine platforms. Numerous studies 
have been devoted to optimizing the DNA vaccine platform to enhance immunogenicity.  
Some of these strategies have been described below:  
Gene modification: Different groups have used different methods to increase antigen 
expression by manipulating transcription elements. Codon optimization is regularly used 
to force the codon usage to favor the target species. This is important because differences 
in codon usage across species can slow down the translation of the microbial gene in 
eukaryotic cells. Optimizing these codons increases the transfer of RNA pools and thus 
enhances gene transcription (André et al., 1998; Deml et al., 2001) 
Other modifications include: the inclusion of termination sites, IgE leader sequences and 
Constitutive Transport Element (CTE). These inclusions provide mRNA stability, proper 
loading of mRNA into ribosomes and increase in protein secretion. Amplifying protein 
secretion through these modifications increases both soluble and membrane bound 
antigen (Wang et al., 2006; zur Megede et al., 2000). This enhances immunogenicity in 
small animals and non-human primates.  
Adjuvants: Traditional Th1 and Th2 cytokines have been successfully used as adjuvants 
to increase immune responses in DNA vaccine studies. Whereas plasmid-encoded 
cytokines can skew the immune response type in vivo, few have shown the ability to 
induce higher effective humoral responses. We began using chemokines, a family of 
small cytokines, in our laboratory as molecular adjuvants when studies revealed that 
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DNA vaccination induced chemokine expression on CD8+ cells. This finding quickly led 
to the cloning of many plasmids encoding chemokines such as MIP-1α, MCP-1, SDF-1, 
IL-8 and RANTES. Cytokines such as IL-2, IL-12, IL-17 and IL-28 have been able to 
enhance the cellular part of the immune response in both mice and monkeys. This 
indicated that our search for improved cellular immune responses against HBV may lie in 
molecular adjuvants.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3-2 
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Summary of the advantages of DNA vaccine  
 
 
 
 
 
 
Figure 3-1 
 
 
Immunogenicity  
 
 
 
 
 
They can induce both humoral and cellular immune responses at 
low effective dosages (micrograms) in animal models 
 
 
Manufacture 
 
 
 
 
Conceptually, they would be inexpensive to produce. 
 
 
Engineering 
 
 
 
 
Plasmid vectors are easy to manipulate and can be tested rapidly 
 
 
Safety 
 
 
 
Unlike live vaccines, they are unable to revert to virulence and 
unlike some killed vaccines they do not require the use of toxic 
treatments. 
 
 
Stability 
 
 
 
 
They are more temperature-stable and have a long shelf life. 
 
 
 
Mobility 
 
 
 
 
They are easy to store and transport. 
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Mechanism of DNA vaccine immunization 
 
 
 
 
 
Figure 3.1 Mechanism of DNA vaccine immunizations. After intramuscular injection 
of DNA plasmid, myocytes and antigen presenting cells are directly transfected. The 
secreted proteins are processed and presented to lymphocytes in the lymph nodes.  
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3.3 Developing a vaccine against HBV core antigen 
 
Resolution of acute HBV is believed to require a strong multi-specific CD4+ T cell 
response to peptides encoded in the core antigen (Ferrari et al., 1990; Penna et al., 1996). 
CD8+ T cells are, however, the main effector cells responsible for HBV clearance via 
both cytolytic and non-cytolytic pathways, induced by the production of cytokines such 
as IFN-γ+, TNF-α+(Biermer et al., 2003; Guidotti et al., 1996; Thimme et al., 2003). As 
such, chronically HBV-infected individuals show decreased in total HBV-specific CD4+ 
and CD8+ T cell responses compared to persons who successfully clear the virus. 
Moreover, CTL responses to the HBV core protein are poorly detected, as patients’ 
ability to generate IFN-γ+  T cells becomes diminished following chronic infection(Chang 
et al., 2005; Reignat et al., 2002). Studies in animals have confirmed the elimination of 
both IFN-γ+ and TNF-α+ producing CD8+ cells during chronic HBV infection (Chang, 
2006). These data together with studies distinguishing HBcAg as the major viral 
determinant of HBV persistence (Lin et al., 2010) highlight the importance of generating 
a strong immune response to HBcAg to resolve HBV infection. 
Currently, the only therapies available for chronically infected individuals are interferon-
α and nucleoside analogue treatments, which function by controlling viral replication but 
unfortunately do not clear infection. Interferon-α can prevent viral replication in only 
30% of patients and does so with undesirable side effects. On the other hand, nucleoside 
analogues are much more effective at inhibiting viral replication but prolonged treatment 
often results in the emergence of escape mutants (Michel and Mancini-Bourgine, 2005). 
The failure of protection by current HBV vaccines in 15% of individuals and the 
difference in response to treatment in chronically infected people may be due to the 
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genetic divergence among different HBV genotypes (Cao, 2009; Lin and Kao, 2011; 
Torresi, 2002), as well as the inability to drive strong HBV-specific cytotoxic 
lymphocytes (CTLs) to the liver.  
In the hopes of addressing these inadequacies with current approaches, we constructed a 
plasmid based on the HBV core (HBcAg)-specific consensus sequence from the Asian 
and African genotypes of HBV with genetic modifications that improve expression of the 
inserts. This includes codon and RNA optimization, as well as additional modifications to 
elicit maximum in vivo expression(Yan et al.). HBV core protein was chosen, as it is the 
major viral determinant of HBV persistence, with one of the major differences between 
acute and chronic human HBV infection being the detection of CTL against HBcAg in 
circulation (Ferrari et al., 1990; Lin et al., 2010; Tsai et al., 1992). Previous data from 
several groups suggest that these CTLs play a crucial role in the clearance of HBV during 
acute infection.  In addition, recent findings suggest that the induction of both cellular 
and humoral immunogenicity against HBV antigens is important for controlling chronic 
infection (Yi-Ping Xing, 2005). Studies from our laboratory and other independent 
groups have shown that plasmid DNA delivery by electroporation (EP) represents an 
important strategy for enhancing cell or antibody mediated immune responses (Hirao et 
al., 2008a; Hirao et al., 2008b; Laddy et al., 2008; Yan et al., 2008), which we examined 
in this study.  
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3.4 Construction of HBcAg plasmid and Expression of pMCore 
 
A consensus sequence of HBcAg was generated from 5 different genotype (A through E) 
gene sequences. The sequences were collected from different countries to avoid a 
sampling bias towards heavily sequenced genotypes. As shown in Figure 3.2a, there was 
an observed relative closeness of the multi-genotype consensus HBcAg sequence to all 
sampled sequences from different genotypes. After the consensus sequence was 
generated, several modifications were performed to increase the antigen expression levels 
from plasmid as described by our laboratory for other plasmid-based vaccines(Shedlock 
et al.; Yan et al.) (Figure 3.2b). 
The HBcAg protein was expressed by transfected pMCore DNA plasmid containing the 
core gene of hepatitis B (Figure 3.2b). An In vitro translation assay (a cell-free system) 
on lysate showed detectable HBcAg at an expected molecular weight of 28 kDa (Figure 
3.3a). The expression was further confirmed using anti-HA tagged monoclonal antibody 
by immunofluorescent assay. We took advantage of confocal imaging to visualize 
HBcAg in the cytoplasm and around the nucleus of tranfected RD cells (muscle cells) as 
shown in Figure 3.3b.  The expression pattern confirmed that a DNA plasmid carrying 
the core gene could be highly expressed in different cells in vitro.  
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Figure 3-2 
 
HBV consensus core DNA construct (pMCore). 
 
 
 
a.  
 
 
 
 
 
 
 
 
 
 
 
 
 
0.02 
M
core 
 75 
Figure 3-2 cont.  
 
 
 
b.  
 
 
 
 
Figure 3.2 HBV consensus core DNA construct (pMCore). (A) Phylogenetic analysis 
of HBcAg consensus sequence as compared to individual genotypes (A through E). (B) 
Schematic representation of plasmid map and sequence of pMCore.  
 
 
MDWTWILFLVAAATRVHSDIDPYKEFGATVELLSFLPSDFFPSVRDLLDTASALYRE 
                 IgELS 
ALESPEHCSPHHTALRQAILCWGELMTLATWVGSNLEDPASRDLVVSYVNTNMG 
LKIRQLLWFHISCLTFGRETVLEYLVSFGVWIRTPPAYRPPNAPILSTLPETTVVRRRG 
RSPRRRTPSPRRRRSQSPRRRRSQSRESQCYPYDVPDYA                 
                                                                                 HA Tag 
IgELS HA Tag 
MCore 
BGH pA
Kan
pUC ori
pCMV
MPol
pMPol
5324 bp
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Figure 3-3 
 
Detection of pMCore expression 
a.  
 
b.  
 
 
Figure 3.3 Detection of pMCore expression via in vitro translation and 
immunofluorescence. (A) Transcription/translation reaction using pMCore plasmid was 
immuno-precipitated with anti-HA monoclonal antibody which recognized a HA epitope 
encoded into the pMCore antigen.  The precipitate was run on SDS-PAGE gel. (B) 
pMCore was detected in transiently transfected cells using a primary monoclonal HA tag 
antibody followed by detection with DyLight 594-labeled anti-rabbit secondary antibody 
(red). Hoechst stain was also used to fluorescently label cell nuclei. Expression of MCore 
is mostly localized to the cytoplasm as shown by the green stating patterns concentration 
outside the nucleus. 
pMCore pVAX 
25 KD 
PVAX 
DAPI Anti-HA Overlay 
pMCore 
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3.5 HBcAg-specific cellular and humoral response 
 
3.5.1 Immunized mice exhibit immune response in the periphery 
 
To better evaluate the generation of T and B cell immune responses, we immunized 
Balb/c mice and measured both responses in various peripheral tissues. Mice received 
three intramuscular immunizations of 30µg of pMcore or pVax followed by 
electroporation as depicted in the immunization scheme (Figure 3.4a). One week after 
the final immunization, pMCore immunized mice showed evidence of strong HBcAg T 
cell responses as identified by IFN-γ ELISPOT assay following ex vivo stimulation.  
Figure 3.4b clearly shows the dominant epitopes are biased towards peptide pool 2.  The 
average HBcAg-specific IFN-γ T cell response induced was robust at 2000 (± 210) SFU 
per million splenocytes.  Interestingly, intracellular staining of stimulated splenocytes 
revealed that both CD4+ and CD8+ cells produce almost the same amount of antigen-
specific IFN-γ and TNF-α with about 0.4% of the T cells being double positive for both 
cytokines (Figure 3.4c and Figure 3.4d). The comparable cytokine production between 
both T cells did not predict their ultimate proliferative capacity. After 4 days of 
stimulation with antigen specific peptides, the CD8+ T cells proliferated more than 2 fold 
higher than the CD4+ cells (Figure 3.4e) showing a clear CD8 T cell bias in the response. 
To further explore the immune response induced in pMCore-immunized mice, we 
analyzed antigen-specific IgG and IgA responses by B cell ELISpot as well as in ELISA 
using splenocytes and sera, respectively, collected following vaccination. A high IgG and 
IgA titer was observed in the sera of immunized mice when compared to control animals. 
B cell ELISpot from immunized mice showed HBcAg-specific IgG and IgA at 
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approximately 200 SFU and 100 SFU per million cells respectively. Figure 3-4b, 
illustrates activation of the B cell compartment by immunization. Thus, our synthetic 
HBcAg plasmid effectively induced antigen-specific cellular and humoral responses after 
3 immunizations.  
3. 5. 2 pMCore drives HBcAg-specific response in the liver 
 
It is hypothesized that increasing functional anti-viral effector T cells in the liver will be 
important to clear chronic HBV infection. However, few studies on HBV vaccines have 
attempted to address this issue. Here, we examined the cytokine producing capabilities of 
intrahepatic antigen-specific T cells after DNA immunization. Both CD4 and CD8 T cells 
isolated from the liver produce IFN-γ and TNF-α when stimulated in vitro with HBcAg 
peptide (Figure 3.5a and Figure 3.5b). While the CD4 T cells show a high percentage of 
double producers of IFN-γ and TNF-α, the CD8 showed little to no IFN-γ+TNF-α+ 
producing cells. Instead majority of the CD8 T cells produced only IFN-γ or TNF-α. We 
also observed enrichment of HBcAg-specific CD4 T cells in the liver as compared to the 
spleen. The percent HBcAg-specific CD4 T cell producing IFN-γ and double positive of 
IFN-γ and TNF-α CD4 T cells in the resting liver was 4 and 2.8 fold higher than that 
observed in the spleen respectively. Conversely, peripheral CD8 T cells were confirmed 
to be better double producers than liver resident CD8 T cells. We also observed antibody-
producing capabilities of liver resident B cells from immunized mice. Interestingly, the 
liver as a mucosal organ produced higher antigen-specific IgA than IgG (Figure 3.5c), an 
important observation that has not been previously been studied.  
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Figure 3-4 
 
pMCore induces strong HBcAg-specific immunity in 
splenocytes of BALB/c mice 
a.  
 
b.  
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Figure 3-4 cont.  
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Figure 3-4 cont.  
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Figure 3-4 cont.  
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Figure 3-4 cont.  
 
 
 
 
 
 
Figure 3.4 Immunization with pMCore induces strong HBcAg-specific immunity in 
splenocytes of Balb/c mice. (A) Immunization scheme. 4 mice were immunized 
intramuscularly with 30µg pMCore. (B) Frequency of HBcAg-specific IFN-γ spot 
forming units (SFU) per million splenocytes after stimulation of spleen cells from 
immunized mice. (C) Average percent HBcAg-specific CD4 or CD8 IFN-γ+, TNF-α+ (D) 
Average percent HBcAg-specific CD4 or CD8 double positive producing cells. (E) 
Percent proliferation of CD4 and CD8 T cells (F) HBcAg-specific humoral immune 
response induced by pMCore. The values are the means ± standard error of the mean. 
Significance was determined by Student’s t test. 
 
 
 
 
 84 
Figure 3-5 
 
Synthetic HBcAg plasmid drives immune response in liver  
a.  
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Figure 3-5 cont.  
 
b.  
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Figure 3-5 cont.  
 
c.  
 
 
 
 
 Figure 3.5 DNA immunization with pMCore drives strong antigen-specific 
immunity in liver of Balb/c mice. (A) Percent HBcAg-specific CD4 and CD8 IFN-γ+, 
TNF-α+ producing cells in the liver. (B) Average percent HBcAg-specific CD4 or CD8 
double positive producing cells. (C) Antigen-specific antibody producing splenocytes. 
The values are the means ± standard error of the mean. Significance was determined by 
Student’s t test.  
 
 
 
 
 
 
 87 
3.6 Immune protection in pMCore immunized mice. 
 
3. 6.1 CD8 T cells from immunized mice specifically kill target 
cells in vivo. 
 
 Next we assessed the ability of HBV-specific CD8 T cells induced after DNA 
immunization to specifically eliminate target cells in vivo. As previously described, 
human CTLs that target the core antigen are important in acute clearance of HBV versus 
chronic infection. One week after the final immunization, 4 mice from each of the two 
groups, pVax or pMCore immunized, were adoptively transferred with target splenocytes 
that had either been pulsed with HBcAg (relevant) or HCV-NS3/4A (irrelevant) peptides. 
By gating on CFSE labeled splenocytes to track killing, we observed that the pMCore 
vaccinated mice were able to induce strong specific killing of antigen-pulsed target cells 
as shown in Figure 3.6. Average percent killing observed in the spleen was about 83% 
while the average in the liver was 76%, showing that vaccine-induced CTLs that migrate 
to and are retained in the liver are capable of killing HBV peptide pulsed target cells. The 
percent killing in the spleen was comparable to previous studies that reported HBcAg-
specific CTL responses using in vitro cytotoxicity assays (Yi-Ping Xing, 2005). To our 
knowledge, this is the first study to show induction of HBcAg-specific CTL responses in 
the liver, by any method and specifically by systemic immunization. These data provide 
evidence that peripheral immunization can induce effector cells that can migrate to the 
liver and lyse target cells.  
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3.6.2 Clearance of HBcAg expressing hepatocytes without any 
evidence of liver injury 
 
In the absence of a small animal model for HBV to examine immune mediated clearance, 
we next utilized HBcAg plasmid to transiently transfect mouse liver through direct 
hydrodynamic injection. This model has been described in studies to acutely transfect 
mouse liver with different types of viral DNA (Lin et al., 2010),(Ahlän et al., 2005; Yang 
et al., 2002). Here, immunized or naive mouse livers were either transfected with 
pMCore or an irrelevant plasmid encoding hepatitis C antigens (HCV NS3/4A). 
Immunohistochemistry staining three days post transfection (Figure 3.7a) shows 
clearance of HBcAg-transfected hepatocytes as compared to the NS3/4A-transfected 
animal livers. CD8 T cells isolated from the pMCore hydrodynamic injected mice in 
Figure 3.7b showed a higher frequency of IFN-γ+ CD107a+, a marker of degranulation, 
as compared to immunized animals livers transfected with the irrelevant plasmid.  
Since the clearance of pMCore-transfected hepatocytes seems to involve degranulation, it 
was fair to assume the killing may lead to liver damage. To examine if immunized mice 
were able to clear the transfected hepatocytes without inducing significant liver damage, 
we employed a widely used assay measuring the enzyme, alanine aminotransferase 
(ALT) which is an indication of liver damage when enzyme levels are observed elevated 
in the sera, Figure 3.7c. These studies showed that the specific clearance of HBcAg-
transfected hepatocytes did not increase ALT levels in transfected immunized animals 
beyond the normal range of 5-30U/L.  
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Figure 3-6 
 
In vivo specific killing 
 
 
Figure 3.6 In vivo specific killing. Two groups of mice immunized with either pVax 
(control) or pMCore received CFSE-labeled target cells (CFSElo pulsed with irrelevant 
peptide or CFSEhi pulsed with epitope-specific peptide) through the tail vain. CFSE-
labeled cells were recovered and analysis by FACS was utilized to quantify percent 
killing.  
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Figure 3-7 
 
Elimination of HBcAg-expressing hepatocytes  
a.  
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Figure 3-7 cont.  
 
b.  
 
 
c.  
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Figure 3-7 cont.  
 
 
Figure 3.7 Degranulation and elimination of HBcAg-expressing hepatocytes by 
vaccine-primed T cells. Hepatocytes of pMCore-immunized mice were transiently 
transfected with HBcAg or HCV NS3/4A plasmid. (A) Immunostaining of liver 
sections taken three days after hydrodynamic injection of PBS, pMCore (HBcAg) or 
pNS3/4A (HCV NS3-4A) from naïve or mice that were immunized with pMcore is 
shown. Clearance is much higher for the pMCore-immunized liver as compared to the 
NS3/4a transfected control liver.   pMcore or NS3/4A expression detected with an anti-
HA antibody (green cells) (B) Serum ALT levels at day 3, 6 and 12 post transfection 
were measured and show no evidence of elevation in relevant vaccinated animals. (C) 3 
days post transfection, cells were analyzed for degranulation marker expression, CD107a, 
and IFN-γ+ expression following stimulation with HBcAg peptides.  
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3.5 Conclusions 
 
Previous studies from other groups have shown induction of either or both cellular and 
humoral responses when murine (Kuhrueber et al., 1997), nonhuman primates (Sällberg 
et al., 1998) or humans (Livingston et al., 1999) were immunized with plasmids or 
retroviral (adenovirus) vectors encoding the core antigen. However, the ability of these 
vaccines to induce and retain antigen specific immune cells in the liver and clear infected 
hepatocytes was not investigated. Furthermore the magnitude of the responses induced in 
this study appear superior to these prior approaches.  In this study, we examined the 
proficiency of a synthetic HBcAg encoded plasmid DNA vaccine delivered in the 
periphery to establish antigen-specific immune response targeting to the liver resulting in 
clearance of HBV transfected liver cells. 
 The immune phenotype induced by this vaccine was interesting. Using intracellular 
staining we observed that antigen specific cells from the spleen of immunized mice were 
double positive for both IFN-γ and TNF-α. Although the plasmid contains a core antigen, 
it is worth of noting the high titer HBcAg-specific IgG and IgA observed in sera. From a 
therapeutic point view, it is important for the activated cells to traffic to and to then be 
retained in the liver.  Immunized mice demonstrated an increase in activated CD4 T cells 
in the liver as evidenced by the large percentage of HBcAg-specific IFN-γ and TNF-α 
double positive cells found there. Liver CD8 T cells on the other hand, were mostly 
single function producer cells. The importance of multiple-cytokine producing CD4 T 
cells in producing effector functions is well described (Kannanganat et al., 2007) but 
single function CD8 and more specifically  intrahepatic T cells in this regard have not 
been previously reported.  However, single function CD8 T cells are likely effector cells. 
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Lu et al. (Yi-Ping Xing, 2005), demonstrated that immunization with HBcAg DNA could 
induce antigen-specific cytotoxic activity in vitro. Our data using an in vivo killing assay 
extended their findings.  The ‘in vivo killing’ assay confirmed that antigen-specific CD8 
T cells in immunized mouse spleen and liver (which were single function CD8 T cells), 
are able to efficiently eliminate target cells.  
In order to assess the effectiveness of an HBV vaccine, a challenge model is needed. In 
the absence of an infectious small animal model, mouse hepatocytes can be transiently 
transfected in vivo by plasmid DNA through a process known as hydrodynamic injection 
to create an “infectious-like” model. Although this model mimics aspects of acute 
infection, it has been used by many independent groups to study viral kinetics(Yang et 
al., 2002), persistence (Lin et al., 2010) and clearance (Yin et al., 2011). We transfected 
naïve and pMCore primed mice liver with the consensus DNA through hydrodynamic 
injection.  Three days after the transfection, degranulation in spleen was evaluated by 
staining CD8 T cells from both groups for CD107a. The immunized group showed higher 
percentage of IFN-γ and CD107a double positive CD8 T cells retained in the liver.  
pMCore-Immunized mice showed complete clearance of HBcAg expressing hepatocytes 
but were ineffective against HCV-NS3 expressing hepatocytes, showing the level of 
specificity of the generated CTL. This specificity of the clearance is relevant to treatment 
of HBV infection, as nonspecific elimination of hepatocytes has been reported to lead to 
inflammation in the liver. There are concerns that cellular immune responses induced by 
vaccines against liver pathogens can drive hepatitis resulting in liver damage. Measuring 
the amount of alanine transaminase  in the blood as means of evaluating liver injury, we 
observed no significant liver damage during or after the liver clearance process. This 
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important finding suggests that antigen-positive hepatocyte clearance might be through 
both cytolytic and non-cytolytic processes as seen during human acute HBV clearance.   
In summary, a synthetic recombinant plasmid encoding HBcAg and delivered by EP can 
generate responses that target to liver, and such responses maybe useful in a prototype 
HBV immune therapy.  Although further studies are needed to understand the trafficking 
and retention of antigen specific T cells in the liver, their ability to induce responses and 
clear infected hepatocytes with minimal damage by what appear to be effector T cells, as 
reported here, is encouraging. Further investigation of these immunization tools in HBV 
with relevance to liver cancer appears important.  
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Chapter 4 – Combined immunotherapy with HBc 
and HBs 
 
 
“ There is no cure for hepatitis B, which is why prevention is critical. Universal 
vaccination at birth is the most effective way to prevent infection and future 
consequences of the disease” – Susan Allan, director of the Oregon department of human 
services and public health division.    
 
4.1 Activating both arms of the adaptive immune response 
 
The current HBV vaccine, which is also the first ever-recombinant vaccine, like most 
vaccines available in the market relies on the induction of antibodies to convey 
protection(Averhoff et al., 1998). This is not very practical for the quarter of a billion 
people around the world who are already infected with the virus and are in a dying need 
of an effective immune therapy(Hosaka et al., 2012). Studies have shown that strong T 
cell responses are seen during the resolution of acute HBV infection(Guidotti and 
Chisari, 1996; Rehermann et al., 1996). In chronic infection however, there is a decline in 
the overall cellular responses and CTL to certain antigens diminishes(Chang et al., 2005; 
Reignat et al., 2002). This highlights the importance on why driving that part of the 
adaptive immune response will be useful in the therapeutic setting. While anti-HBsAg 
has been the hallmark of protection for the current vaccine (using antibodies), 
immunization against the HBcAg has shown to drive stronger cellular immunity in small 
animals, non-human primates and humans (Kosinska et al., 2012; Livingston et al., 1999; 
Zu Hu Huang, 2001). Together, these studies highlight the importance of driving both 
arms of the adaptive immune response to multiple antigens in the search for a successful 
therapeutic HBV vaccine.  
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The cell-mediated immune responses will help clear infected hepatocytes by inducing 
cytotoxic T cells (Tc). These types of lymphocytes kill infected cells by releasing 
cytotoxins such as granzymes and perforins. A vaccine-induced Tc will in theory be 
activated by recognizing processed HBc or HBs antigens on the MHC I of the infected 
cells. The Tc will release perforins, which will form pores in the membranes of the target 
(infected) cells, and then release granzymes, which will enter these target cells to initiate 
a caspase cascade. The activation of the various caspase domains will lead to the 
apoptosis of the target cell.  
The humoral immune response on the other hand, does not have direct effect on the 
infected cells. However, antibodies can help contain infection by activating a mechanism 
called Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) to destroy infected 
cells. HBc or HBs antigen-specific antibodies will bind to infected cells expressing these 
antigens on their cell surfaces. This antigen-antibody complex will attract natural killer 
cells to destroy the infected hepatocytes in a fashion similar to the cytotoxicity induced 
by CTLs. Antibodies can also neutralize viruses that move out of infected hepatocytes to 
infect neighboring cells. Viruses that ‘bud’ out of infected cells have the potential to 
infect other cells if the immune cells do not destroy them.  
Driving both arms of the immune response using different antigens may prove to be the 
most effective approach for a hepatitis B therapeutic vaccine. DNA vaccination seems to 
be the appropriate platform to develop this type of vaccine. DNA vaccines, unlike protein 
or peptide vaccines, can elicit robust T cell responses and CTL(Bagarazzi et al., 2012; 
Shoji et al., 2012). Additional manipulations during the delivery process such as the use 
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of electroporation has enhanced the humoral responses to a significant titer(Shoji et al., 
2012). More importantly, DNA vaccines are safe and very malleable (Kutzler, 2008).  
4.2 Developing synthetic DNA HBs encoded immunogens 
 
4.2.1 Construction and expression of multiple HBsAg DNA 
vaccine 
 
Previous studies from our laboratory and other independent groups have suggested that 
the use of consensus immunogens in the context of vaccines is important in inducing a 
more broad immune response as compared to immunization with one native immunogen. 
Here, we generated DNA constructs encoding either the major S or the preS1/S2 plus the 
major S of the HBsAg consensus sequence for HBV genotypes A and C in attempt to 
increase the breadth of the immune response against the HBsAg proteins. Clustal X 
(version 1.8) software was used to create multiple alignments needed to generate a single 
consensus sequence, Figure 4-1a.  
Following construction and optimization of the constructs, protein expression of each 
plasmid was confirmed by immunofluorescence. RD cells were transiently transfected 
with individual constructs or with an empty pVax vector as a control.  The cells were 
fixed 48 later and stained with full-length HBsAg polyclonal monkey sera. Fluorochrome 
labeled anti-human IgG confirmed the protein expression (not shown). The expression 
was further confirmed using flow-cytometry. Transfected Hep G2 cells were 
intracellularly stained with sera from immunized mice and commercially available mouse 
monoclonal antibody (Figure 4.1c).  
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Figure 4-1 
 
HBV surface antigen DNA constructs. 
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Figure 4-1 cont.  
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Figure 4-1 cont.  
 
c. 
 
 
 
Figure 4.1 HBV Surface antigen DNA constructs. (A) Phylogenetic analysis of pHBs 
consensus sequences of HBS as compared to individual genotypes of A and C. (B) 
Plasmid map of pLHBs and pSHBs showing IgE leader sequence and endoproteolytic 
cleavage sites. (C) Detection of pLHBs and pSHBs via intracellular staining of 
transfected RD cells with monoclonal antibody and polyclonal mouse sera. 
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4.2.2 Immunogenicity of the individual HBsAg plasmids  
 
After expressing the surface antigens in vitro, we evaluated the ability of the different 
HBV surface antigen constructs to individually induce antigen-specific humoral and 
cellular responses in vivo. Balb/c mice were intramuscularly immunized thrice, 2 weeks 
apart at week 0, 2 and 4 with 15µg of plasmids expressing either the small or large S 
antigen or a pVax control. The injection sites were electroporated (EP) immediately 
following injection. We first looked at the humoral response induced by the constructs, 
since DNA vaccines have not always been consistent in generating significant amount of 
antibodies. We performed an antibody ELISA to analyze antigen-specific IgG responses 
in sera collected from mice 7 days after each immunization.  The ELISA plates were 
coated with recombinant full length HBsAg protein for this analysis. Both pLHBs and 
pSHBs from either genotype were greatly immunogenic. They induced significant levels 
of HBsAg-specific IgG antibodies following the initial immunization. Continued 
immunization boosted these responses, showing the greatest enhancement at week 2 after 
the third immunization (Figure 4.2a). In contrast, the mice immunized with the pVax 
control developed background IgG responses. Although we observed differences in 
response with each group, the progressive enhancement after each immunization was 
similar within the groups.  
We next looked at the ability of pLHBs-A, pLHBs-C, pSHBs-A and pSHBs-C constructs 
to induce cellular immune responses as determined by IFN-γ ELISPOT. The surface 
antigen-specific IFN-γ secreting cells were analyzed in response to two pools of synthetic 
peptides from consensus large HBV surface protein. The first pool contains the N-
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terminal domain of the protein (preS1) and an additional 55 amino acid preS2 domain. 
Although all four consensus constructs were able to induce strong T cell response 
(Figure 4.2b), there is clearly an epitope-bias towards the major S protein. We also 
observed strong cross immune reactivity within the two genotypes. These results indicate 
that our synthetic DNA immunogens encoding either the full length or only the major S 
portion of the HBV surface antigen exhibit immunogenicity that is diverse enough to 
protect against the major genotypes of HBV. 
4.2.3 Breadth and magnitude of the cellular immune responses  
 
After confirming the magnitude of cellular response of against the synthetic plasmids, we 
determined whether there was also an increase in the breadth of cellular immune 
responses against genotype-specific targets by detailing the cellular immune responses 
against HBsAg major S and preS1/S2 peptides in both BALB/c mice. The data suggested 
that there was no clear dominant epitope induced by the synthetic surface antigen 
plasmids in the BALB/c mouse strain. For pLHBs, there were 12 matrix pools out of 16 
for genotype A and 8 out of 16 for genotype C, showing more than 50 spots. With 
pSHBs, there were 9 matrix pools out of 12 pools for genotype A and 12 out of 12 matrix 
pools demonstrating more than 50 spots in vaccinated BALB/c mice (Figure 4-3). These 
data signify that there is a significant increase in the breadth and magnitude of cross-
reactive cellular responses induced by each of the 4 HBs constructs. 
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Figure 4-2 
 
Immune responses induced by each HBs DNA plasmid. 
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Figure 4-2 cont.  
 
b.  
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Figure 4-2 cont.  
 
 
 
 
 
Figure 4.2 Immune responses induced by each HBs DNA plasmid. Five Balb/c mice 
per group were immunized and analyzed for their induction of both humoral and cellular 
responses (A) Antibody responses from individual HBs constructs to native HBsAg 
proteins one week after each immunization. (B) Stimulated splenocytes showed increased 
magnitude and cross reactivity of cellular responses in both genotype A and C.  
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Figure 4-3 
 
Enhanced breadth of the cell-mediated immune responses  
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Figure 4-3 cont.  
 
b.  
 
 
Figure 4.3 Enhanced breadth of the cell-mediated immune responses.  (A-D) All four 
constructs showed broad T cell immunogenicity. Many dominate epitodes were observed 
with these constructs.  
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4.3 Combined therapy 
 
4.3.1 Immunogenicity of HBsAg-HBcAg DNA cocktail 
 
Since immunization with all four synthetic HBsAg plasmids elicited broad cross-reactive 
immune responses, we next combined these plasmids with HBcAg plasmids to generate a 
DNA vaccine cocktail for immunization. The core antigen of HBV is known to be critical 
for viral clearance through the induction of HBcAg-specific CTL responses. We 
proposed that the cocktail will enhance the previously observed cellular response by 
increasing the number of immune epitopes the host cell will recognize within the virus. 
Mice were either immunized with cocktails containing only the surface antigens (both 
genotypes) or with cocktails containing both the surface antigens and a consensus core 
antigen plasmid (pMCore) that has been previously described (Table 4.1).  The HBsAg 
only groups showed high antibody titer in sera of immunized mice. Similar titers were 
seen in the major S plus pMCore group but not in the LHBs-pMCore cocktail group 
(Figure 4.4a).  
To further explore the immune response elicited by the HBsAg-pMCore immunized 
mice, we evaluated the IFN-γ spots per million induced by stimulated splenocytes from 
each group. The average SFU per million splenocytes for groups with no pMCore were 
about 670 and 1200 against genotype A and genotype C peptides respectively. 
Importantly, the addition of pMCore on average increased the total SFU per million 
splenocytes by 400 spots against genotype C and doubled the response when the 
splenocytes were stimulated with the genotype A peptides (Figure 4.4b).  
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CD8+ T cells are known to be the main effector cells responsible for HBV clearance and 
therefore, it is important to determine which cell type is responsible for the IFN-γ 
production. It is also essential to examine if these T cells can induce multiple antiviral 
activity in response to antigenic re-encounter by releasing other antiviral cytokines (TNF-
α and IL-2) and degranulation markers such as CD107a. Intracellular staining of 
stimulated splenocytes revealed multi-cytokine producing activated CD8 T cells within 
all groups (Figure 4.5a - f). We also observed the induction of lymphocyte degranulation 
marker, CD107a in these CD8 T cells. It is noteworthy to mention that CD8 T cells from 
HBsAg-HBcAg groups showed significant higher poly-functional activity when 
stimulated with the surface antigen peptide.  
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Table 4-1 
 
Immunization groups for combined HBV therapy 
 
 
Groups 
 
DNA cocktail 
 
 
Group 1  
 
 
pVax 
 
Group 2  
 
 
pLHBs-A / pLHBs-C 
 
 
Group 3 
 
 
pSHBs-A / pSHBs-C 
 
 
Group 4 
 
 
pLHBs-A / pLHBs-C / pMCore 
 
 
Group 5 
 
 
pSHBs-A / pSHBs-C / pMCore 
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Figure 4-4 
 
HBc/HBs vaccine cocktail induces robust immune responses 
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Figure 4-4 cont.  
 
b.  
 
 
Figure 4.4 HBc/HBs vaccine cocktail induces robust immune responses. (A) 
Antibody responses from sera of mice immunized with HBs/HBc vaccine cocktail at 
different immunization time points (B) IFN-g responses after ex vivo stimulation of 
splenocytes from HBs/HBc cocktail immunized mice.  
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Figure 4-5 
 
Antigen-specific CD8 T cells induce antiviral cytokines 
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Figure 4-5 cont.  
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Figure 4-5 cont.  
 
 
Figure 4.5 Antigen-specific CD8 T cells induce antiviral cytokines.  Intracellular 
staining of anti-viral cytokines after ex-vivo stimulation of splenocytes from immunized 
balb/c mice.  
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4.4 Non-human primates 
 
4.4.1 Immunization of macaques with HBsAg-HBcAg cocktail 
 
In the past, some DNA vaccines that have been very immunogenic in small animal 
models such as mice. However, they typically lost effectiveness when studied in larger 
animals. Encouraged by the strong antibody and T cell responses incited by the 
combination of pLHBs or pSHBs and pMCore in mice, we decided to evaluate the 
immunogenicity of the combined constructs in a larger animal model. To ensure better 
induction of the cellular immune response, we added a molecular adjuvant. We used one 
of the best-described molecular adjuvant in non-human primates, IL-12. IL-12 is a Th1 
polarizing cytokine that drives cellular immune responses by aiding the priming and 
expansion of CD8 T cells.  This adjuvant has been used to enhance the immune response 
against different antigens from various pathogens.  
Rhesus macaques were immunized IM/EP with pLHBs/pMCore, pSHBs/pMCore and 
pLHBs/pMCore/IL12 four times, 4 weeks apart. The animals were bled once before the 
first immunization and 2 weeks following each immunization. Humoral immune 
responses to HBV surface antigen were determined using commercial HBsAg proteins 
were in sera ELISA assay. High titer antibody responses were seen after two 
immunizations with pSHBs/pMCore but not with pLHBs/pMCore. The response against 
pLHBs/pMCore was boosted after the third immunization. The IL-12 adjuvant enhanced 
the antibody titer of the pLHBs/pMCore cocktail immunization after just two 
immunizations (Figure 4.6a)  
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The animals’ immune responses to these cocktails were determined with IFN-gamma 
ELISpot assays. Figure 4.6b shows the sum of each monkey’s response to both HBs and 
HBc peptide pools, as well as the average group response for each of the three time 
points. Little to no antigen-specific cellular immune responses were detectable following 
the pre-bleed and the first immunization. However, after the third immunization the 
responses increased significantly over 2000 SFU/106 PBMCs, with the IL-12 adding over 
1000 SFU/106 PBMCs to the pLHBs/pMCore cocktail.  
Intracellular staining with antibodies to antiviral cytokines reveals antigen-specific 
production of antiviral cytokines such as IFN-g, TNF-a and IL-2 by both CD4 and CD8 T 
cells from immunized monkeys. Figure 4.6c shows the total percent of HBV-specific 
CD4 and CD8 cytokine producing cells.  
4.4.2 Broad cellular immune response in Rhesus macaques 
 
Similar to the immunization in small animals, the immune response was not directed at 
few dominant epitopes of pHBs. The majority of immunized monkeys (four out of five) 
from group A were able to elicit strong cellular immune responses to at least 10 or more 
peptide epitopes of pLHBs. Although only two out of the five monkeys from group B 
showed strong immunogenicity to 10 or more peptide epitopes, their responses to the 
matrix peptide pools predict a diverse response. Group C had three monkeys that 
responded to more than 10 peptide epitodes. This suggests that the Rhesus macaques 
were able to elicit cellular immune responses against multiple sites within the HBV 
surface proteins (Figure 4.7). Therefore, the DNA cocktail immunization of surface and 
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core HBV antigens is able to elicit both strong and broad cellular responses against the 
HBs proteins in Rhesus macaques.  
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Figure 4-6 
 
Immunogenicity in non-human primates 
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c.  
 
 
 
 
 
 
 
Figure 4-6 cont.  
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Figure 4.6 Immunogenicity in non-human primates. (A) Immunization groups. Five 
Rhesus Macaques were immunized intramuscularly followed by electroporation. The 
monkeys received three immunizations, 4 weeks apart.  High antibody titers to HBs were 
determined after the last immunization. (B) IFN-g responses were measured once before 
the first immunization and 2 weeks following each immunization. 
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Figure 4-7 
 
Broad T cell responses in immunized monkeys 
 
 
 
 
 
Figure 4.7 Broad T cell responses in immunized monkeys.  All five monkeys from 
each group responded broadly to multiple peptide epitopes.  
 
 
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12
0
50
500
1000
1500
peptide pool
S
F
U
/1
0
6
 P
B
M
C
s
1 2 3 4 5 6 7 8 9 10 11 12
0
50
500
1000
1500
2000
peptide pool
S
F
U
/1
0
6
 P
B
M
C
s
1 2 3 4 5 6 7 8 9 10 11 12
0
50
500
1000
1500
2000
2500
peptide pool
S
F
U
/1
0
6
 P
B
M
C
s
Group Monkey ID Positive Matrix Pools Positive Peptide Epitopes 
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5022 3, 4, 5, 6, 7, 8, 9, 10 16 
4943 1, 2, 5, 6, 7, 8, 11 12 
4942 1, 2, 4, 5, 10, 11 10 
4954 2, 5, 10 2 
Group B 4628 1, 4, 5, 6, 7, 8, 9, 10, 11 20 
5018 1, 2, 3, 7, 10 6 
4941 5, 6, 8, 11 4 
4938 1, 2, 3, 4, 5, 6, 8, 11 12 
4939 5, 6, 9 2 
Group C 4639 1, 2, 3, 4, 8, 9, 10, 11 16 
4945 1, 2, 3, 4, 5, 6, 9, 10, 11 18 
4946 5, 6, 7, 8, 9 6 
5015 1, 2, 4, 5, 6, 7, 8, 9, 11 20 
5019 4, 5, 9 3 
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Figure 4-8 
 
A hepatitis DNA vaccine appears safe in non-human primates  
 
a – b.  
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Figure 4-8 cont.  
 
 
 
 
 
Figure 4.8 A hepatitis DNA vaccine appears safe in non-human primates. Samples 
were analyzed prior to vaccination (4/3/2012), after the third vaccine (7/24/2012), and 
after the fourth vaccination (9/18/2012 and 10/25/2012). There was an assay error for 
alkaline phosphatase on 7/24/2012. The normal range for all measures is depicted by 
dashed lines.  A) Serum alkaline phosphatase. B) Serum alanine aminotransferase (ALT) 
levels. C) Serum aspartate aminotransferase (AST) levels. (D)Serum total billirubin 
levels. E) Serum Creatinine levels. F) Serum blood urea nitrogen (BUN) levels. 
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4.5 Conclusions 
 
In this study we report the ability of a multivalent synthetic hepatitis B DNA immunogen 
cocktail to elicit both antibody and cell-mediated immunity against the surface and core 
antigens of this virus. Immunization of small animal models with either vaccine by itself 
generated the necessary immune response needed for protection. It has however, become 
clear over the years that both antigens are important during the resolution of acute and 
chronic HBV infection. We therefore believe that the combination of multiple HBV gene 
plasmids encoding different proteins will revolutionize the future of immunotherapy 
against the pathogen. 
Global routine vaccination against the hepatitis B virus (HBV) has prevented both acute 
and chronic infection of the virus in millions of people across the world(FitzSimons et 
al.). The virus infects human hepatocytes and causes liver cirrhosis which can lead to 
hepatocellular carcinoma, a deadly form of cancer that claims over 700, 000 lives each 
year(El-Serag, 2004; Llovet et al., 2003).  There are four major human HBV serotypes 
(adr, adw, ayr and ayw) and eight genotypes (A through H) that have been characterized. 
Genotypes A and C are most commonly found in the Americas, Asia and Africa(Cassidy 
et al., 2011; Shi, 2012).  
Though the current HBV vaccine that targets the surface antigen (HBsAg) of the virus 
has demonstrated to be effective in inducing protective antibodies following three 
vaccination routines(Carollo et al.; Huang et al., 2011; Lemon and Thomas, 1997), 10-15 
percent of individuals fail to respond and remain at risk of infection. In addition, there are 
about 370 million people chronically infected with virus and at the risk of developing 
liver cancer (WHO, 2000). Most of these chronic infected individuals have no access to 
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the expensive therapies available. Those who are on therapies receive drugs with 
undesirable side effects, which only reduce viral replication and not clearance.  
The first generation of HBV vaccines became available in the 1980s when vaccinologist, 
Maurice Hilleman and his group treated and filtered blood sera from infected individuals. 
Concerns over the safety of this vaccine led to their termination and the creation of the 
second and third generation vaccines using the recombinant protein technology(Maupas 
et al., 1976; Shepard et al., 2006). The second-generation vaccine uses the major part of 
the HBsAg (major S), excluding several amino acids at the N-terminal of the surface 
protein (pre-S1 and pre-S2) known to support viral attachment and entry. The third 
generation vaccine, which included both the pre-S1 and pre-S2, produced a stronger 
immune response (Raz et al., 1996; Schumann et al., 2007). These recombinant protein-
based HBV vaccines although safe, require several in vitro molecular manipulations and 
production at large scale in yeast or CHO cells. Like most recombinant protein-based 
vaccines, these vaccines lack the ability to drive strong cell mediated immunity 
(CMI)(Chen et al., 2011; Shen et al., 2010). It is therefore important to develop an 
effective immune therapy that will induce strong cellular immunity and protective 
antibodies in all vaccinated individuals.  
Here, we developed four different HBsAg DNA vaccines to the two most common 
genotypes (A and C) and examined their ability to drive immune responses. We utilized 
the same gene optimization approach from previous studies to increase the magnitude of 
these responses. While all plasmids shared the major S (SHBs) amino acid segment of the 
HBs gene, only two had the pre-S1 and pre-S2 segments (LHBs). The amine-terminus 
domain of the preS1 is believed to assist viral attachment and entry while the carboxyl 
 129 
terminal end of preS2 is important for infectivity. Antibodies raised against the pre-S2 are 
known to prevent viral infection both in vivo and in vitro (Glebe, 2007; Shen et al., 2010). 
We therefore, reasoned that the inclusion of both segments in our vaccine would increase 
immunogenicity. We saw no significant difference in HBV native protein-specific 
antibodies between the pLHBs and SHBs constructs. Balb/c mice immunized with either 
immunogen elicited broad cellular immune responses. More importantly, these responses 
showed cross reactivity between the two genotypes.  
As stated previously, the core antigen is an important aspect of the virus in terms of 
prevention and clearance of the infected hepatocytes. Studies in our laboratory have 
shown DNA vaccine encoding the HBcAg to drive strong Th1-cell immunity and 
subsequent clearance of HBV in the liver (Obeng-Adjei, 2012b). We hypothesize that a 
vaccine cocktail that includes plasmids encoding both HBcAg and HBsAg will be 
advantageous in the search for an effective immune therapy. This cocktail will not only 
drive both cell-mediated and antibody immunity, but will also increase the breadth and 
magnitude of both responses. Our findings confirmed a synergistic effect in CD8 T cell 
antiviral cytokines like IFN-γ, TNF-α and IL-2, and degranulation marker, CD107a. 
More importantly, animal models immunized with these cocktails were able to clear cells 
that were transfected with either antigen. While there was a reduction in antibody 
response for the LBHs constructs, the plasmids encoding only the major S genes 
maintained the humoral responses achieved through the single vaccine immunization. 
These responses provide evidence that a therapeutic vaccine that clears infected 
hepatocytes and prevents continuous infection of other hepatocytes can be achieved if 
multiple genes and epitopes are targeted.  
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In all, we have shown that recombinant plasmid vaccines encoding different parts of the 
three co-carboxyl terminal surface proteins contained in HBV can induce strong humoral 
and cellular responses. Morover, the combination of these plasmids with synthetic DNA 
vaccines, which encode HBcAg drives multi-epitope responses and clears infected cells. 
Although further investigation is needed, it is apparent that this immunization tool will be 
useful in the search for immunotherapy for HBV.   
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Chapter 5 – Discussion and Future Directions 
 
“Medical science has proven time and again that when the resources are provided, great 
progress in the treatment, cure, and prevention of disease can occur.” – Michael J Fox, 
Actor. 
 
5.1 Significance 
 
For the liver to perform metabolic activities such as plasma protein synthesis, glycolysis, 
processing digested compounds and detoxifying the body of harmful unfamiliar 
chemicals, it requires a steady stream of blood to be delivered through the hepatic artery 
and the portal veins. This implies that the liver is constantly exposed to harmless food 
antigens and intestinal commensal bacteria. In the interest of avoiding constant 
inflammation that may lead to bystander damage of the liver, the liver is believe to bias 
immune responses towards tolerance (Yang et al., 1994).  This tolerogenic effect is 
evident through allogeneic liver transplantation.  
In contrast to other tissues such as the kidney and heart, the liver is readily accepted 
without immune-suppression when grafted in small animal models. In primates, less 
immunosuppressive therapy is required for liver transplantation than other organs (Calne 
and Davies, 1994; Qian et al., 1997). showing that T cell rejection by liver recipients is 
very low. Although this level of tolerance is beneficial in keeping the liver safe from the 
host immune defense system, it opens the liver up for infection by pathogens looking to 
escape the immune system. Pathogens such as Hepatitis B, Hepatitis C and the 
Plasmodium that causes malaria have habitually taken advantage of the liver’s ability to 
suppress the immune response. These pathogens use liver cells as a site for infection, 
replication, amplification and most importantly, a site to hide from the view of any 
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immune surveillance. Unfortunately, these simple goals of those pathogens are not so 
trouble-free for the host. When Hepatitis B and Hepatitis C are left untreated, they 
become chronic and lead to various liver complications that can result in death. Although 
malaria does not cause any extensive liver problems, it is known to take many lives 
around the world each year through its manifested symptoms.  
In spite of this well acknowledged liver tolerance, there are circumstances where there 
are sufficient immune responses in the liver to clear pathogenic infections. The best 
example is Hepatitis A, where the host more often than not clears the infection from the 
liver. In acute Hepatitis B and Hepatitis C, infected individuals incite enough of an 
immune response to clear the pathogens and mount immunological memory. In an effort 
to understand and utilize the immune responses induced within the liver, researchers 
discovered that liver cells like LSECs and hepatocytes could prime certain aspects of the 
adaptive immune system. These cells act like professional antigen presenting cells by 
taking, processing and presenting antigens to naïve T cells, specifically, CD8 T cells 
(Knolle, 2000). Albeit controversial, many in vivo and in vitro experiments have shown 
that these CD8 T cells die promptly after activation to induce tolerance in the liver 
(Bertolino et al., 1999; Bertolino et al., 1998). Other studies show that activated CD8 T 
cells stay around long enough to clear pathogens from the liver (Wuensch et al., 2010). 
Although the exact consequences of liver CD8 T cell activation is debatable, researchers 
agree that further investigations into hepatic T cell priming can be beneficial to the 
development of therapeutic and prophylactic immune therapies to hepatotropic 
pathogens.  
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We investigated this phenomenon by directly comparing liver primed CD8 T cells to 
secondary lymphoid tissue primed CD8 T cells for differentiation, function, and memory 
programming in a highly controlled fashion. We used hydrodynamic tail vain injection of 
plasmid to establish a liver-specific transient expression of LCMV-gp antigen, and 
studied priming of CD8 T cells using the P14 transgenic mouse model. This study was 
important to understand the dynamics of CD8 T cells, which play a vital role in the 
clearance of intracellular pathogens. We identified features that are similar between 
intrahepatically activated CD8 T cells and attributes that help push the liver environment 
into a toleragenic state, with respect to cellular immune responses.  
While comparing and contrasting intrahepatic T cell activation to lymphoid activation, 
we observed migration of effector CD8 T cells to the liver after intramuscular 
immunization with synthetic DNA plasmids. Knowing the importance of intrahepatic 
antigen-specific T cells in the clearance of HBV and HCV, we made it our goal to 
develop therapeutic DNA vaccines, which will induce functional antigen-specific T cells 
that can clear infected cells in the liver after peripheral immunization. We selected HBV 
as a model because it is the only pathogen out of the three successful human liver 
pathogens that has an effective prophylactic vaccine. Although the HBV vaccine has 
been in use for over three decades, there are many chronic infected individuals that are in 
need of an effective therapeutic vaccine. The selective recruitment of T cells to the liver 
and the clearance of HBV-transfected hepatocytes by cytotoxic T cells after 
intramuscular DNA immunization with electroporation suggest that the DNA vaccine 
platform is an important candidate for HBV immune-therapy.  
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5.2 Intrahepatic CD8 T cell priming 
 
In this project, we report an unexpected defect in the initial induction of adaptive immune 
response during LCMV expression and a non-inflammatory priming of CD8 T cells in 
the liver. Priming of naïve CD8 T cells in the liver compromises the cells’ expansion 
capacity, causing a decrease in effector and memory cell frequency in the spleen, lymph 
nodes, liver and lungs. Although intrahepatic CD8 T cell priming resulted in early 
effector differentiation, the overall quality of the effector functions was somewhat 
comparable to CD8 T cells primed in lymphoid tissues. The memory cells’ poor antigenic 
clearance and viral control illustrate their low CTL frequency.  
 An acute infection model was used to elucidate the effector differentiation and memory 
programming of CD8 T cells post liver priming. We utilized the hydrodynamic DNA 
plasmid injection approach to establish an acute liver infection. The expression of the 
antigen of interest was exclusive to the liver and lasted for only 4 days, mimicking acute 
liver infection.  
With this model, LCMV DbGP33-specific CD8 T cell priming in P14 chimera mice was 
confirmed by the up-regulation of effector molecules. By using models that ensure the 
exclusion of CD8 T cell priming in lymphoid tissues, we observed proliferation and 
expansion of GP33+/Thy1.1 cells in P14 chimeras after intrahepatically expressing 
cognate viral Ag. Collectively, these data make hydrodynamic plasmid injection an 
acceptable model for Ag-specific, secondary lymphoid Tissue-independent CD8 T cell 
activation.  
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To clear pathogenic infection, CD8 T cell priming alone is not sufficient. The activated 
CD8 T cell should be able to survive long enough to differentiate into a mature effector 
population that possesses antiviral properties. Some groups believe that intraheptatic 
activated CD8 T cells upregulate pro-apoptotic markers and therefore lack the ability to 
survive long enough to have any impact on viral resolution. This Bim-dependent deletion 
of liver-primed CD8 T cells has been linked with the inability of HBV-specific CD8 T 
cells to control viral persistence in chronic infections (Lopes et al., 2008). We observed 
an early proliferative response of naïve CD8 T cells with the hydrodynamic injection 
method compared to the traditional IM immunization model, where T cell activation is 
deemed to occur in the draining lymph nodes. This early cell division of antigen specific 
CD8 T cells was consistent with data in the literature, which shows the kinetics of initial 
intrahepatic priming to be more rapid than an SLT-dependent one (Lukens et al., 2009). 
The early proliferation of these DbGP33-specific CD8 T cells in intrahepatic (IH) groups 
was followed by untimely effector cell contraction. These CD8 T cells expanded early 
but the cell frequency at the peak of expansion was several folds lower than CD8 T cells 
primed in the draining lymph nodes. As expected the pro-apoptotic marker, Bim, was up 
regulated in the IH group during this contraction phase. The Bim levels in the 
Intramuscular (control) group eventually caught up with the IH group during its peak of 
expansion. Interestingly, the survival signal, Bcl-2, in the IH group was down-regulated 
in the first week when Bim was high but increased during the second and third weeks 
postimmunization. Thus, this data contradicts the idea that intrahepatic activated CD8 T 
cells undergo abortive activation. This is the first study to show that liver-primed CD8 T 
 136 
cells, albeit hastily, experience the same death and survival phases as CD8 T cells in 
acute viral infection.  
In addition to the phenotypic examination of liver-primed CD8 T cells’ effector 
differentiation status, we also analyzed their functional properties. While some studies 
claim full functional differentiation (Wuensch et al., 2006), a more comparative analysis 
of these effector cells disclosed defective anti-viral activity (Lukens et al., 2009).  Our 
findings confirm that these liver-primed effector CD8 T cells can secrete anti-viral 
cytokines. Though they were inferior single antiviral cytokine producers, their 
polyfunctionality, a property reported to correlate with protection (Betts et al., 2006), was 
considerably similar to the control group in all tissues except the lymph nodes. It is 
noteworthy to mention that lymphoid-primed effector CD8 T cells recovered from the 
liver were less functional than those in the spleen and lymph nodes. Therefore, we 
believe that the liver milieu may play a crucial role in effector suppression. Moreover, the 
liver activated CD8 T cells mounted a strong cell-mediated cytotoxic effect upon antigen 
re-encounter. This important finding thus demonstrates that effector CD8 T cells induced 
through liver priming can be as effective as those primed in the lymphoid tissues.  
Although several independent groups have shown T cell priming and their effector status 
using liver cells as primary APCs (Crispe, 2011), to our knowledge prior studies have not 
shown if these cells can become long-lived memory cells. Our results reveal that a subset 
of effector cells (memory precursor effector cells) likely to become long-lived memory 
cells can be detected in the liver-primed effector CD8 T cell population. Increased 
expression of memory-markers on these cells was observed a few weeks after 
immunization. Although liver-primed CD8 T cells differentiate into memory cells 
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quicker than lymphoid primed cells, the distribution of effector, effector-memory and 
central memory cells were similar in all tissues within the groups. Crispe et al. believe 
that direct liver priming of CD8 T cells promotes the expression of inhibitory molecules 
such as PD-1 (Wuensch et al., 2010). We did not observe a significant increase in PD-1 
expression for the IH group. The liver microenvironment seems to up-regulate PD-1 on 
both naïve and effector cells, regardless of the priming site. Naïve Thy1.1 cells 
transferred into unimmunized Thy1.2 recipients, maintained a higher level PD-1 
expression in the liver compare to spleen and lymph node over a period of time. 
Additionally, HBV persistence in mice has been shown to increase PD-1 expressing CD8 
T cells in liver infiltrating lymphocytes (Tzeng et al., 2012). Thus, the increased 
expression of PD-1 on memory CD8 T cells after intrahepatic activation in their model 
may be a consequence of continued antigen expression in the liver and not an undesirable 
effect from liver-priming.  
We evaluated recall and effector differentiation of these long-lived memory CD8 T cells 
in both lymphoid and non-lymphoid tissues. The IM group responded and eliminated 
target cells from all tissues upon secondary challenge. In contrast, the hydrodynamically 
injected group was deficient in killing these Ag-pulsed target cells. This lack of killing 
was associated with a low frequency of effector-memory cells in the IH group. Although 
the IH group’s memory precursors comprise about 16% of peak effector cells, the 
frequency was still very low due to its lower effector frequency. As predicted, 
hydrodynamic immunized mice repeatedly succumbed to lethal dose LCMV intracranial 
(i.c) challenge.  
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The results presented in this study show that the lack of recall response needed to protect 
mice from secondary challenge after liver-priming of CD8 T cells is directly associated 
with a defect in the initial clonal expansion. This is in direct comparison to human studies 
which have shown that lack of viral clearance in chronic HBV and HCV infections 
correlates with a low number of HBV or HCV-specific CD8 T cells detected in the 
blood(Sobao et al., 2001; Sobao et al., 2002).  
 
5.3 Therapeutic Hepatitis B vaccine 
 
With this project we showed that a cocktail of synthetic plasmids encoding Hepatitis B 
DNA immunogens is capable of eliciting robust antibody and cell-mediated immunity to 
the surface and core antigens of this hepatotropic virus. Both the surface and the core 
antigens of HBV have been shown to be essential during the resolution of both acute and 
chronic HBV infection. Although the current HBV prophylactic vaccine only targets the 
surface antigen, there are many studies that have shown that the core antigen can also 
drive a strong cell mediated immune response. Our studies show that synthetic DNA 
plasmids encoding the core antigen can drive immune responses in both spleen and liver 
when delivered intramuscularly with electroporation. Furthermore, immunized mice 
displayed strong cytotoxic responses that eliminate adoptively transferred HBV-coated 
target cells. Importantly, vaccine-induced immune responses provided protection from 
HBcAg plasmid-base liver transfection in a hydrodynamic model. This provided 
important insight into the generation of peripheral immune responses that are recruited to 
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the liver - an approach that will be beneficial in generating a potential theraupeutic HBV 
vaccine.  
We developed two different plasmids encoding different parts of the surface antigen. 
While all plasmids shared the major S (SHBs) amino acid segment of the HBs gene, only 
the pLHBs had the pre-S1 and pre-S2 segments (LHBs). The amine-terminus domain of 
the preS1 is believed to assist viral attachment and entry, while the carboxyl terminal end 
of preS2 is important for infectivity. Antibodies raised against the pre-S2 are known to 
prevent viral infection both in vivo and in vitro (Glebe, 2007; Shen et al., 2010). 
Therefore, we reasoned that the inclusion of both segments in our vaccine would increase 
immunogenicity. We saw no significant difference in HBV native protein-specific 
antibodies between the pLHBs and SHBs constructs. Balb/c mice immunized with either 
immunogen elicited broad cellular immune responses. More importantly, these responses 
showed cross reactivity between the two different genotypes, A and C.  
Immunization of small animal and non-human primate models with a cocktail of both 
core and surface vaccines generated a high magnitude and broad cellular and humoral 
responses. We observed the clearance of infected skin cells from guinea pigs after HBs-
HBc vaccine cocktail immunization. We believe that the combination of multiple HBV 
gene plasmids encoding different proteins will revolutionize the future of immunotherapy 
against this pathogen in infected individuals.  
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5.4 Future directions 
 
Providing CD4 help during intrahepatic priming:  
Hepatocytes and Kupffer cells are believed to be the two main cells involved in the 
priming of naïve CD8 T cells in the liver. Their ability to cross present antigens to naïve 
CD8 T cells is due to the fact that they express major histocompatibility complex class I 
(MHC I) on their surfaces. However, their inability to express class II MHC (MHC II) 
means they cannot prime CD4 T cells (Crispe, 2011; Wuensch et al., 2010). CD4 T cells 
or T helper cells provide help to other adaptive immune cells by releasing cytokines that 
are essential for immune cell activation and growth. T helper cells assist with class 
switching and maturation, of B cells, while it helps maximize CD8 T cells’ cytotoxic 
activity.  
While the presence of CD4 help is not crucial for CD8 T cell priming, it is believed to be 
essential in CD8 T cell expansion and the generation of long-lasting memory cells. 
Recent data have also shown that lack of CD4 help results in poor recall responses and 
antiviral cytokine production in effector CD8 T cells (Derkow et al., 2011; Shedlock and 
Shen, 2003).  
With this knowledge, we believe the observations made after priming naïve CD8 T cells 
in the liver may have been skewed due to the absence of CD4 help. Our model however 
lacks the ability to induce or measure CD4 T cell priming. We hope to use other models 
such as OT II, which recognize OVA peptides, to compare and contrast intrahepatic and 
lymphoid CD8 T cell priming, with and without CD4 help. 
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Using IL-28 cytokine as an adjuvant: 
 
The three members of the interferon λ family, IFNλ 1 (IL-29), IFNλ 2 (IL-28A) and 
IFNλ 3 (IL28B) have been shown to be secreted by innate immune cells in response to 
viral infections.  More importantly, these cytokines place immune cells in an antiviral 
state, which is vital in slowing down or preventing viral replication (Uzé and Monneron, 
2007).  
IL-28B in particular has been a subject of studies in hepatitis diseases since a significant 
clinical link was made between the levels of IL-28B in human sera and response to 
Hepatitis C therapies. Studies show that a single nucleotide polymorphism (SNP) near the 
IL28B gene may increase HCV patients’ response to treatments with interferon and 
ribavirin (Ge, 2009).  
Studies from our laboratory illustrate that when IL28B is used as an adjuvant in DNA 
vaccine immunization, it increases antigen-specific anti-viral cytokine production. This 
augmentation in cellular immune responses led to an increased protection. In that, mice 
that were co-immunized with influenza antigen and IL-28B were protected from lethal 
H1N1 challenge (Morrow et al., 2009; Morrow et al., 2010). These data were 
reproducible in non-human primate models, where we saw an increased in anti-viral 
cytokines when macaques were co-immunized with the IL-28B adjuvant (Morrow et al., 
2010). Utilizing one of the most effective adjuvants in the DNA vaccine platform, IL-12, 
in HBV primate studies (chapter 4), we observed increased IFN-γ responses in monkeys 
that received an HBs-HBc vaccine cocktail with IL-12 adjuvant. We also observed an 
increase in HBs-specific IgG in the sera of the immunized monkeys.  
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In the future, we hope to immunize both mice and monkeys with our HBV vaccine 
cocktail and IL-28B adjuvant to study the effect this adjuvant will have on the induction 
of immune responses against HBV viral antigens.  
 
Clinical trials 
The lack of appropriate primate models to hepatitis B, such as chimpanzee, means we 
have to rely on the strong immunogenicity induced in rhesus macaques to move our 
therapeutic vaccine into clinical studies.  In December of 2011, the National Institute of 
Health (NIH) placed a temporary moratorium on new studies using chimpanzees. 
Chimpanzees are currently the only known primates that have pathology that resembles 
human hepatitis disease after infection with HBV.  
Fortunately, the strong safety record of DNA vaccines in human studies means we are 
likely to move the HBV DNA vaccines into clinical trials without any protection studies 
from higher primates. The group likely to receive this vaccine will be chronically infected 
individuals who are already on antiviral therapy. The patients will be monitored after 
receiving the vaccine for any liver damage. If any increase in ALT is observed, they will 
be removed from the studies and placed on steroids to suppress the immune responses.  
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Chapter 6 – Materials and Methods 
 
 
6.1 In vitro Experiments 
 
 
6.1.1 Media  
 
D10 medium: Dulbecco’s modified Eagle’s medium plus 10% fetal bovine serum (FBS) 
and 1 × antibiotic-antimycotic agent.  
R10 medium: Roswell Park Memorial Institute medium plus 10% FBS and 1 × 
antibiotic- antimycotic agent.  
 
6.1.2 DNA plasmid preparation    
 
 
Construction and modification of novel HBcAg consensus sequence 
A HBV genotype A, B, C, D and E Core consensus nucleotide sequence was constructed 
by generating consensus sequences of core genes for each genotype and then generating a 
consensus sequence of all five genotype consensuses, thus avoid biasing toward heavily 
sequenced genotypes. The sequences were aligned using clustal X software to develop 
the final HBcAg consensus sequence. Once the group consensus sequence was obtained, 
we introduced several modifications, including the addition of a highly efficient IgE 
leader sequence and a C-terminal HA tag, and the construct was RNA and codon 
optimized. The synthesized HBcAg was digested with EcoRI and NotI, and cloned into 
the expression vector pVAX (Invitrogen) under the control of the cytomegalovirus 
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immediate-early promoter and this construct was then named as pMCore(Obeng-Adjei, 
2012a). 
Obtaining LCMV-GP mutant DNA 
This plasmid construct was a gift from Dr. Rafi Ahmed of Emory University, Atlanta, 
GA. It contains the full length LCMV-GP with 5 mutations. Only two of the mutations 
are in a specific epitope sequence. One of those two mutation changes GP33 epitode 
ending with Methionine to Cysteine. 
GP33: KAVYNFATM → KAVYNFATC 
GP92: CSANNSHHY→ SANNPHHY 
 
Synthesizing DNA plasmids encoding Hepatitis B surface antigen  
Two consensus constructs were generated for hepatitis B surface antigen genotype A and 
genotype C. The sequences were attained from the Genebank, picked from different 
countries to prevent sampling errors. The sequences were then optimized for expression, 
including codon and RNA optimization (GeneArt, Regens- burg, Germany). These 
constructs were then synthesized and inserted into the pVAX1 expression vector 
(Invitrogen).  
6.1.3 DNA transfection and Protein expression    
 
DNA plasmid transfection 
1 μg of DNA plasmid was used to transfect cell lines such as RD (muscle) cells, 293( 
human embryonic kidney) cells, HepG2 (hepatic) cells.  Transfection reagent Turbofectin  
8.0 was used as recommended by the manufacturer’s guidelines.  
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In vitro translation Assay  
Expression of DNA plasmid was detected using TNT® Quick Coupled Expression of 
Transcription/Translation System containing 35S-methionine (Promega, Madison, WI). 
The synthesized gene product was immuno-precipitated using an anti-HA monoclonal 
antibody targeting an encoded HA epitope, Clone HA-7 (Sigma-Aldrich). The immuno-
precipitated protein was electrophoresed on a 12% SDS-PAGE gel and subsequently 
fixed and dried. The synthesized protein with incorporation of radioactive 35S was 
detected by autoradiography. 
 
Western Blot Analysis  
Western blotting analysis was performed according to standard protocols. 10 μg per well 
of lysed protein was run on a SDS-PAGE gel (Cambrex, Rockland, ME), blotted on 
nitrocellulose membrane, and probed with commercial antibody. The signal was 
amplified using an anti-mouse IgG-HRP (Zymed) and detected with ECL (GE 
Healthcare, Chalfont St. Giles, United Kingdom).  
 
Immunofluorescence  
Rhabdomyosarcoma (RD) cell lines were transfected with pMCore using TurboFectTM 
(Thermo Scientific) according to manufacturer’s guidelines. The cells were first fixed 
with 2% formaldehyde and then assayed for protein expression. The fixed cells were 
incubated with rabbit monoclonal HA tag (Invitrogen) diluted in ‘primary standard 
solution’ (0.1% BSA, 0.2% saponin, 0.02% sodium azide) for an hours at room 
temperature. The cells were subsequently incubated with DyLight 594-labeled anti-rabbit 
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secondary antibody (Thermo Scientific) for 20 minuets at room temperature. Images were 
obtained using a Zeiss Axiovert 100 inverted confocal microscope. Analysis and 
quantification of florescence intensities were conducted using Image J software (NIH, 
Rockville, MD).   
 
Histology.  
For histology, tissues isolated from mice were fixed for 24 h in 4% paraformaldehyde. 
These are then place in 30% sucrose for 24 hours, frozen in OCT ((Frozen tissue matrix) 
and cut on a cryostat. The sectioned tissues were stained and images were obtained using 
a Zeiss Axiovert 100 inverted confocal microscope. Analysis and quantification of 
florescence intensities were conducted using Image J software (NIH, Rockville, MD). 
 
6.2 Murine studies 
 
6.2.1 In vivo Experiments   
 
Mice  
 
C57BL/6 mice (CD90.2) were purchased from Jackson Laboratories (Bar Harbor, ME). 
CD90.1+ P14 mice bearing the Db-GP33−specific TCR (Pircher, 1989a) were a gift 
from Dr. John Wherry of University of Pennsylvania. All mice were maintained in 
specific pathogen-free facilities at the University of Pennsylvania. The University of 
Pennsylvania Institutional Animal Care and Use Committee (IACUC) approved all 
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protocols, and all experiments were performed according to the guidelines of the 
University of Pennsylvania IACUC.  
P14 chimeric 
 
 Mice were generated by adoptively transferring 1 x 105 naive TCR transgenic T cells 
into naive B6 mice (referred to as P14 chimeras)(Wan et al., 2003). For FTY720 
experiment, FTY720 was dissolved in sterile water at 2.5 µg/ml /ml for treated mice 
while control mice receive normal drinking water(Masopust et al., 2010). For L-selectin 
experiments, treated mice received 200µg/ml MEL-14 (anti-CD62L) blocking antibody 
intravenously (I.V)(Harp et al., 2010) 4 hours prior and 24 hours post adoptive transfer of 
P14 cells.  
 
 Intramuscular Immunization/Electroporation 
For IM immunization studies, animals were divided into groups. Each animal in the 
immunized group received one or three intramuscular immunizations of a specific DNA 
plasmid with concentrations ranging from 5 to 30µg. Multiple immunizations were 
performed two or three weeks apart. For better generation of memory cells, 
immunizations were performed 1 month apart.  Each immunization was accompanied by 
in vivo electroporation with the CELLECTRA® adaptive constant current electroporation 
device (Inovio Pharmaceuticals, Blue Bell, PA). Two 0.2 Amp constant current square-
wave pulses were delivered through a triangular 3-electrode array consisting of 26-gauge 
solid stainless steel electrodes completely inserted into muscle. Each pulse was 52 
milliseconds in length with a 1 second delay between pulses (Hutnick et al., 2011). 
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Hydrodynamic tailvain immunization  
For hydrodynamic tail vein immunization (HDTV), mice were injected intravenously 
with 200µg of plasmid in 2mL (about 10% volume of the mouse weight) of PBS solution 
within a period of 7 seconds to transiently transfect the liver(Zhang et al., 1999). 
 
Mouse Sacrifice and Tissue Collection 
 
One week after final immunization, the mice were sedated with 2,2,2 tribromoethanol 
(Avertin), a mouse anesthetic; retro-orbital bleeding was performed before the mice were 
sacrificed by cervical dislocation. Spleens, lymph nodes, liver, lung, brain, skin, heart, 
muscle, kidney, intestine and Peyer’s patches were be harvested into a 15-ml conical tube 
containing R10 medium. Tissues needed for histology were fixed with 2% PFA. For 
those needed for lymphocyte isolation, the tissues were put through a cell strainer and 
treated with ACK lysing buffer. Cells were then washed twice with R10 media, counted, 
and used for the appropriate experiments (West et al., 2011).  
 
 Splenocyte isolation and purification 
Splenocytes were isolated as described elsewhere(Shedlock et al.). In brief, mice were 
sacrificed one week after the last immunization and spleens were harvested, placed in 
R10 media (RPMI media supplemented with 10% FBS and 1x Anti-Anti). The spleens 
were individually crushed, strained with a 40μM cell strainer and treated with 1mL ACK 
lysis buffer for 5 min to lysis erythrocytes. The splenocytes were resuspended in a 
complete R10 media and used for further immunological assays.  
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PBMC isolation 
Less than 1 mL of blood was collected from each mouse into individual tubes containing 
500μL sodium citrate.  2mL of R10 was added to the mixture and underlied with 3 mL 
Ficoll. The solution was then centrifuged for 20 mins at 2000 rpm with no breaks.  The 
buffer coat was obtained and lyphocytes were isolated from it. The cells were then treated 
with ACK lysis buffer to lyse the red blood cells.   
 
 Lymphocyte isolation from liver and Lung 
Lymphocytes from liver and lung were obtained as described elsewhere (Choo et al., 
2010). Briefly, each liver was perfused by directly injecting 1mL of PBS into the hepatic 
vein of each mouse. A small incision was made in the heart and PBS was injected into the 
right ventricle of the heart to perfuse the lungs. Both liver and lung were harvested, 
crushed and resuspended in 5mL of 44% isotonic percoll. The lung was first treated with 
EDTA and collagenase. The mixtures were underlied with 3mL 66% isotonic percoll and 
centrifuged for 20 minutes at 2000rpm for gradient separation. Lymphocytes were 
collected and washed in 10 mL R10 and treated with ACK lysis buffer as necessary.  
 
In vivo Cytotoxicity Assay 
 
An in vivo cytotoxicity assay was performed as previously described (Barber et al., 2003; 
Durward et al., 2010). Briefly, splenocytes from naïve mice were stained with either 1µM 
(high) or 1nM (low) CFDA SE (Invitrogen). The labeled splenocytes were then coated 
with the indicated peptides (relevant or irrelevant peptides). Equal frequency of each 
target cell population was intravenously injected into naïve or immunized mice. 24, 48, 
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72 or 90 hours cells post transfer; cells from the blood, spleen or liver were isolated and 
analyzed by flow cytometry. The percent killing was calculated as follows: 100 - ([(% 
relevant peptide pulsed in infected/% irrelevant peptide pulsed in infected)/(% peptide 
pulsed in uninfected/% irrelevant peptide pulsed in uninfected)] x 100).  
 
In vivo Proliferation Assay 
The in vivo cell proliferation assay using CFSE labeling has been previously described. 
Briefly, fleshly isolated splenocytes were stained with the carboxyfluorescein diacetate, 
succinimidyl ester (CFDA-SE) Cell Tracer Kit (Invitrogen) in a prewarmed PBS for 
10min as per the manufacturer’s instructions. Stained cells were washed three times with 
cold saline and suspended in R10 media. The cells were washed twice in the complete 
R10 media and washed three times in serum free media.  The cells were then resuspended 
at one million or appropriate frequency per mL. The cells were then transferred into naïve 
mice through the tail vain with a 28-gauge needle.  
 
Viral Challenge 
For lethal challenge studies, mice were challenged I.C with 200 PFU of LCMV 
Armstrong as previously described(Shedlock et al., 2011) in 30 µl of RPMI. Mice were 
observed daily for 3 weeks, a time point known to be adequate in the LCMV intracranial 
challenge model, and all LCMV infected animals were housed in BSL-2 facilities. 
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6.2.2 Ex vivo Experiments 
 
Interferon-gamma ELISpot 
IFN-γ ELISpot was performed as previously described(Kutzler et al., 2005). 
MultiScreenTM-IP 96-well plates (Millipore, Bedford, MA) were coated overnight at 
4°C with capture antibody diluted in PBS at a concentration of 7.5 μg/mL (anti-IFN-γ 
clone GZ-4, Mabtech, Cincinnati, OH). Plates were washed five times with PBS and 
blocked with complete culture medium for two hours.Splenocytes were stimulated with 
two pools of 15-mer peptides spanning the entire length of pMCore and over lapping by 8 
amino acids.   200,000 splenocytes in R10 media were plated in a 96 well IFN-γ capture 
antibody (R&D system) coated plate and stimulated overnight in the presence of a 
specific peptide pool at 37OC in 5% CO2. Cells were washed out and plates were washed 
five times. The plates were then incubated overnight with 100 μl/well of biotinylated 
detection antibody diluted in PBS (1 μg/mL; clone 7-B6- 1, Mabtech). Plates were 
washed five times with PBS and then incubated with 100 μl/well of streptavidin-alkaline 
phosphatase diluted in PBS (1:1000) for 1 hour at room temperature. Plates were then 
washed five times with PBS and developed with 100 μl/well BCIP/NBT substrate 
solution for 10-20 minutes at room temperature. Washing the wells three times with tap 
water terminated the colorimetric reaction. Plates were air- dried and the spots were 
counted using an automated ELISpot reader system (CTL Analyzers, OH) with the 
ImmunoSpot® software. The mean number of spots from triplicate wells was adjusted to 
1 million splenocytes. The antigen-specific responses were calculated after subtraction of 
spots formed in response to culture medium alone. In addition, a response that was at 
several-fold higher than the medium control was considered positive.  
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Ex vivo Proliferation Assay 
The T cell proliferation assay using CFSE labeling has been previously 
described(Shedlock et al., 2010). Briefly, fleshly isolated splenocytes were stained with 
the carboxyfluorescein diacetate, succinimidyl ester (CFDA-SE) Cell Tracer Kit 
(Invitrogen) in a prewarmed PBS for 10min as per the manufacturer’s instructions. 
Stained cells were washed three times with saline and suspended in R10 media and plated 
in a 96-well U-bottomed plate in a total volume of 200 µL of stimulating media. The cells 
were incubated at 37OC for 96 hours. After 48 hours, 50% of the culture media were 
removed and replaced with fresh R10. Following staining, cells were washed twice in 
PBS and fixed with 1% paraformaldehyde. For flow cytometry, cells were gated on 
singlets using SSC-H by SSC-A followed by gating on CD3+ T cells to examine live T-
cell populations. Pure CD4+ and CD8+ T cell populations were determined by sequential 
CD4 and CD8 gating to account for upregulation of CD8 on activated CD4+ T cells.  
 
Intracellular Cytokine Staining  
A subset of splenocytes was resuspended in R10 media at a concentration of 107 per mL 
and 100µL was plated onto a 96 well round bottom plate. 100µL of media containing 
specific pooled peptides or 10 ng/ml PMA (Sigma, St. Louis, MO, USA) and 500ng/ml 
ionomycin (Calbiochem, Novabiochem, La Jolla, CA, USA) mix as a positive control or 
0.1% dimethyl sulfoxide (Sigma, St. Louis, MO, USA) as a negative control. All wells 
contained 5uL/mL of two protein transport inhibitors, brefeldin A (GolgiPlug) and 
monensin (Golgistop) (All from BD Bioscience). The cells were incubated at 37OC in 5% 
CO2 for 5 hours and stained with LIVE/DEAD® Fixable Dead Cell Stain (invitrogen) for 
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10min at 37OC. Cells were washed twice in PBS and once in PBS containing 5% FBS 
and 0.5% sodium azide. Extracellular staining was performed using antibodies specific to 
mouse CD3, CD4 and CD8 at 4OC for 20 min. These antibodies were diluted in PBS 
containing 5% FBS and 0.5% sodium azide. Spleenocytes were then permeabilized and 
washed using BD Cytofix/CytopermTM and Perm/WashTM (BD Bioscience) respectively. 
The cells were then washed twice with Perm/WashTM solution (BD Bioscience) and then 
stained intracellularly with antibodies to mouse Interferon-gamma, interleukin 2 and 
Tumor Necrosis Factor- alpha. The cells were incubated at 4OC for 1 hour. The cells were 
then washed four times with Perm/WashTM solution and twice with PBS. Following 
staining, cells were fixed with PBS containing 2% paraformaldehyde. The cells were then 
stored at 4OC until flow cytometry analysis.  
Cells were analyzed on a modified LSR II flow cytometer (BD Immunocytometry 
Systems, San Jose, CA). One million events were collected per sample. Data analysis was 
performed using FlowJo version 9.3 (TreeStar, San Carlos, CA). Initial gating used a side 
scatter area (SSC-A) versus height (SSC-H) plot to remove doublets. The events were 
subjected to a lymphocyte gate by a SSC-A versus FSC plot. Live T cells were identified 
by a live/dead versus CD3+ plot. Following this, events are sequentially gated on 
CD8+and CD4– events versus IFN-γ to account for down- regulation. Following 
identification of CD8+ and CD4+ T cells, a gate was made for each respective function 
using combinations that provided optimal separation. After the gates for each function 
were created, we used the Boolean gate platform to create the full array of possible 
combinations, equating to 15 response patterns when testing 4 functions. Data are 
reported after background correction.  
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Conjugated anti-mouse antibodies were used during the extracellular and intracellular 
staining including: CD3- Phycoerythrin/Cy5 (PE/Cy5), CD4- peridinin chlorophyll 
protein (PerCP), CD8- allophycocyanin (APC), IFN-γ-Alexa Fluor 700, TNF-a- 
fluorescein isothiocyanate (FITC) and IL-2-phycoerythryin cyanine (PE) (all from BD 
Biosciences, San Jose, CA)(Wherry et al., 2003).  
 
Measurements of the Sera Ag-specific IgA and IgG levels 
High-binding ELISA plates (Costar, Corning, NY) were coated with 1μg/ml antigen 
specific protein in PBS, at 4°C for 24 hours and then were washed three times with 0.1% 
PBS-Tween. The plates were blocked with PBS containing 1% BSA for 2 hours at room 
temperature and then washed 3 times with PBS containing 0.1% Tween. Serially diluted 
serum samples were added to the wells and incubated for 1 hour at room temperature. 
Plates were then washed five times with 0.1% PBS-Tween. After washing, bound serum 
Antibody was revealed by HRP-labeled goat anti-mouse IgA or IgG. 100uL of HRP-
conjugated IgA or IgG antibody was added to the plate and incubated at room 
temperature for one hour. The plates were washed three times. The peroxidase-
conjugated antibodies were detected using tetramethylbenzidine (Sigma-Aldrich) as the 
substrate. The reaction was stopped with 2N sulfuric acid and OD values at 450 nm were 
measured with the Multiscan ELISA Plate Reader. IgG or IgA end-point titers were 
defined as the reciprocal serum dilution that resulted in OD values that were greater than 
twice the average OD value of the BSA wells.  
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6.3 Macaque studies 
 
Vaccination:  
Fifteen Indian Rhesus Macaques were housed at Bioqual (Rockville, MD) according to 
the standards of the American Association for Accreditation of Laboratory Animal Care. 
The short group consisted of five animals vaccinated with 1.0 mg each pMCore, pSHb A, 
pSHb C delivered IM with in vivo electroporation The long group consisted of five 
animals vaccinated with 1.0 mg each pMCore, pLHb A, pLHb C delivered IM with in 
vivo Electroporation. The Long+12 group consisted of five animals vaccinated with 1.0 
mg each pMCore, pSHb A, pSHb C and 0.04mg plasmid expressed optimized rhesus IL-
12 delivered IM with in vivo electroporation. DNA was delivered to a single site in the 
quadriceps followed by in vivo EP with the constant current CELLECTRA® device 
(Inovio Pharmaceuticals, Blue Bell, PA) with 3 pulses at 0.5 A constant current, a 52 ms 
pulse length and 1 s rest between pulses. Animals were vaccinated at weeks 0, 4, 12 and 
30. 
Sample collection:  
Animals were bled 2 weeks following each immunization. Blood (20 mL at each time 
point) was collected in EDTA tubes and PBMCs were isolated using standard Ficoll-
Hypaque procedure with Accuspin tubes (Sigma-Aldrich). An addition 5 mL blood was 
collected into clot tubes and sera aliquotted for analysis. Inguinal Lymph node biopsies 
were taken at week 0, 14 and 32. Lymphocytes were isolated by physical separation with 
a scalpal and passed through a 16 gauge blunt needle before being passed through a 40 
um filter. Lymphocytes were spun down and frozen for later analysis.  
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ELISpot:  
Matching HepB consensus core, surface antigen A and surface antigen C 15 mer peptides 
were synthesized by Genescript (Piscataway, NJ) and resuspended in DMSO and pooled 
at an approximate final concentration of 1 mg/mL for each peptide.  Cellular responses 
were measured using IFN-g ELISpot (MabTech, Sweeden) following the manufacturer’s 
instructions. Samples were run in triplicate with an R10 (RPMI 1640 containing L-
glutamine with 10% heat inactivated fetal bovine serum, and 1% Penicillin/Streptomycin) 
and a PMA/IM (PMA 0.1 µg/mL and ionomycin 0.5 µg/mL, Sigma Aldrich, St. Louis, 
MO) control.  
Mapping ELISpot:  
To map the epitopes within the HepB core protein, a 6x5 peptide matrix was created. 
PBMCs collected 4 weeks following the third vaccination were stimulated with the 11-
peptide pools. All responses were background subtracted and any responses over 50 
SFU/106 PBMCs was considered positive. Two monkeys had high background levels and 
were excluded from the analysis.  
ELISA: The ELISA assay was performed as previously described using 5 µg/mL HepB 
surface antigen type Ad (MyBioSource) in PBS-T (PBS with 0.5% Tween 20) . Endpoint 
titers were determined as previously reported. Briefly, the upper prediction limit of SIV-
specific IgG antibodies was calculated using the Student t-distribution where the 
mathematical formula that defines the upper prediction limit is expressed as the standard 
deviation multiplied by a factor based on the number of naïve controls and a 95% 
confidence interval. The endpoint titer is reported as the reciprocal of the lowest dilution 
that remained above the upper prediction limit.  
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